リウマチ・膠原病診療マスト＆ベスト

出版社： 診断と治療社
著者：
発行日： 2023-07-10
分野： 臨床医学：内科  >  膠原病/リウマチ
ISBN： 9784787825728
電子書籍版： 2023-07-10 （電子版）
書籍・雑誌
≪全国送料無料でお届け≫
取寄せ目安：8～14営業日

8,800 円(税込)

購入する
電子書籍
章別単位での購入はできません
ブラウザ、アプリ閲覧

8,800 円(税込)

購入する

商品紹介

本書は，フィジカルアセスメントや病歴聴取をしっかり行って，関節の痛みや臓器障害から，(1)リウマチ・膠原病を疑い，そして適切な検査をして，(2)リウマチ・膠原病を診断することの2本柱で構成となっています．また，リウマチ・膠原病疾患に苦手意識のある若手医師や非専門医がリウマチ・膠原病疾患の疑いのある患者を診る際に，スムーズに診断まで進められるアプローチの方法など，すぐに役立つ知識がちりばめられています．

目次

  •  1 総論
    1 リウマチ・膠原病診療の考え方

     2 診断編
     section０：診断への近づき方
    1 リウマチ・膠原病疾患へのアプローチ

     section１：痛みから考える
    1 関節痛・関節炎のアプローチ
    2 頸の痛み
    3 肩の痛み
    4 肘の痛み
    5 手の痛み
    6 腰の痛み
    7 股関節の痛み
    8 膝の痛み
    9 足の痛み
    10 全身が痛い

     section２：障害臓器から考える
    1 眼病変
    2 皮疹
    3 肺病変
    4 胸水
    5 腎臓
    6 尿の色・量
    7 ネフローゼ症候群か腎炎症候群で腎での異常を疑うとき
    8 ネフローゼ症候群か腎炎症候群以外での異常を疑うとき
    9 肺高血圧症（PH）
    10 心嚢水
    11 中枢神経障害
    12 末梢神経障害
    13 消化器疾患
    14 リンパ節腫脹

     section３：不明熱を考える
    1 不明熱の原因になりうる膠原病

     section４：検査の考え方
    1 自己抗体の使い方・考えかた
    2 尿検査の診かた・考えかた
    3 検尿の診かた―定性検査と沈渣
    4 腎機能の診かた
    5 画像検査の診かた
    6 関節穿刺の方法・解釈
    7 腎生検を行うべき病態は？

     section５：診断をつけにいく
    1 全身性エリテマトーデス（SLE）
    2 全身性強皮症（SSc）
    3 筋炎―皮膚筋炎/多発性筋炎（DM/PM），封入体筋炎（IBM），壊死性筋症（NM）
    4 Sjogren症候群（SS）
    5 混合性結合組織病（MCTD）
    6 関節リウマチ（RA）
    7 血管炎
    8 大型血管炎―高安動脈炎（TA），巨細胞性動脈炎（GCA）
    9 結節性多発動脈炎（PAN）
    10 ANCA関連血管炎（AAV）
    11 多発血管炎性肉芽腫症（GPA）と顕微鏡的多発血管炎（MPA）
    12 好酸球性多発血管炎性肉芽腫症（EGPA）
    13 脊椎関節炎（SpA）
    14 リウマチ性多発筋痛症（PMR）
    15 IgG4関連疾患（IgG4-RD）
    16 結晶性関節炎
    17 成人Still病（ASD）
    18 Behcet病
    19 抗リン脂質抗体症候群（APS）
    20 再発性多発軟骨炎（RP）
    21 クリオグロブリン血症
    22 化膿性関節炎
    23 ウイルス性関節炎（PBV19，HBV，HCV，風疹ウイルス）
    24 膠原病で起こる腎疾患

     3 治療編
     1 薬剤の使い方
    1 ステロイドの使い方
    2 非ステロイド性抗炎症薬（NSAID）の使い方
    3 免疫抑制薬の考え方（ステロイドスペアリング）
    4 薬剤性腎障害
    5 腎障害時の薬剤使用―薬剤投与時のeGFRの正しい使い方
    6 高血圧の診かた・降圧薬の使い方
    7 慢性腎臓病（CKD）の管理

この書籍の参考文献

参考文献のリンクは、リンク先の都合等により正しく表示されない場合がありますので、あらかじめご了承下さい。

本参考文献は電子書籍掲載内容を元にしております。

1 総論

P.12 掲載の参考文献
1) Suresh E:Laboratory tests in rheumatology:A rational approach. Cleve Clin J Med 2019;86:198-210.
 
2) Aletaha D, et al.:2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581.
PubMed
3) Watts R, et al.:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-227
 
4) McGonagle D, et al.:A Proposed Classification of the Immunological Diseases. PLoS Med 2006;3:e297.
PubMed
5) Croskerry P, et al.:Cognitive debiasing 1:origins of bias and theory of debiasing.. BMJ Qual Saf 2013;22(Suppl 2):ii58-ii64.
 
Croskerry P, et al. 著, 綿貫聡, 他 監訳:「誤診」はなくせるのか?-実践知としての診断エラー学の世界. 医学書院, 2019(Croskerry P, et al.:Diagnosis:Interpreting the Shadows. CRC Press, 2017).
 
Kahneman D著, 村井章子 訳:ファスト&スロー-あなたの意思はどのように決まるか?, 上・下. 早川書房, 2012(ハヤカワ・ノンフィクション文庫, 上・下, 2014)(Kahneman D:Thinking, fast and slow. Farrar, Straus and Giroux, 2011).
 

2 診断編

P.19 掲載の参考文献
Croskerry P, et al.:Diagnosis:Interpreting the Shadows. CRC Press, 2017(Croskerry P, et al. 著, 綿貫聡, 他 監訳:「誤診」はなくせるのか?-実践知としての診断エラー学の世界. 医学書院, 2019).
 
萩野昇:ロジックで進めるリウマチ・膠原病診療. 医学書院, 2018.
 
P.28 掲載の参考文献
1) Aletaha D, et al.:2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581.
PubMed
2) Gormley G, et al.:Can rheumatologists agree on a diagnosis of inflammatory arthritis in an early synovitis clinic? Ann Rheum Dis 2001;60:638-639.
 
3) Pinals RS:Polyarthritis and fever. N Engl J Med 1994;330:769-774.
PubMed
Lawry GV, et al.:Anatomy of joints, general considerations, and principles of joint examination. In:Lawry GV, et al. eds.:Fam's Musculoskeletal Examination and Joint Injection Techniques, 2nd ed. Mosby Elsevier 2010:1-5.
 
van Vollenhoven RF:Evaluation of Monoarticular and Polyarticular Arthritis. In:Firestein GS, et al., eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2020:663-677.
 
上野征夫:リウマチ病診療ビジュアルテキスト, 第2版. 医学書院, 2008:6-34.
 
P.36 掲載の参考文献
1) Gross AR, et al.:Exercises for mechanical neck disorders:A Cochrane review update. Man Ther 2016;24:25-45.
PubMed
2) Barnsley L:Neck pain. In:Hochberg MC, et al., eds.:Rheumatology, 7th ed. Elsevier, 2019:621-671.
 
3) Kolfenbach JR:Approach for the patient with neck and low back pain. In:Kolfenbach JR, ed.:Rheumatology Secrets, 4th ed. Elsevier, 2020:474-480.
 
4) Carragee EJ:The clinical use of magnetic resonance imaging in pyogenic vertebral osteomyelitis. Spine(Phila Pa 1976)1997;22:780-785.
PubMed
P.46 掲載の参考文献
1) Beuerlein MJS, et al.:The Shoulder. In:Lawry GV, et al., eds.:Fam's Musculoskeletal Examination and Joint Injection Techniques, 2nd ed. Mosby Elsevier, 2010:7-19.
 
2) Hermans J, et al.:Does this patient with shoulder pain have rotator cuff disease?:The Rational Clinical Examination systematic review. JAMA 2013;310:837-847.
PubMed
3) Ochi J, et al.:MRI findings of the shoulder and hip joint in patients with polymyalgia rheumatica. Mod Rheumatol 2015;25:761-767.
PubMed
Hoppenfeld S, et al. 著, 野島元雄 監訳, 首藤貴, 他 訳:図解 四肢と脊椎の診かた. 医歯薬出版, 1984(Hoppenfeld S, et al.:Physical Examination of the Spine and Extremities. Appleton-Century-Crofts, 1976).
 
P.52 掲載の参考文献
1) Lawry GV, et al.:The elbow. In:Lawry GV, et al., eds.:Fam's Musculoskeletal Examination and Joint Injection Techniques, 2nd ed. Mosby Elsevier, 2010:21-28.
 
2) Stanley D:The elbow. In:Hochberg MC, et al., eds.:Rheumatology, 7th ed. Elsevier, 2019:621-671.
 
P.65 掲載の参考文献
1) van den Bosch WB, et al.:The diagnostic accuracy of the squeeze test to identify arthritis:a cross-sectional cohort study. Ann Rheum Dis 2015;74:1886-1889.
PubMed
2) Zhang W, et al.:EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis:report of a task force of ESCISIT. Ann Rheum Dis 2009;68:8-17.
PubMed
3) Nakajima A, et al.:Prevalence of patients with rheumatoid arthritis and age-stratified trends in clinical characteristics and treatment, based on the National Database of Health Insurance Claims and Specific Health Checkups of Japan. Int J Rheum Dis 2020;23:1676-1684.
PubMed
4) Marshall M, et al.:Hand osteoarthritis:clinical phenotypes, molecular mechanisms and disease management. Nat Rev Rheumatol 2018;14:641-656.
PubMed
5) Gran JT, et al.:The incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis:a prospective study of 231 cases. Rheumatology(Oxford) 2000;39:283-287.
PubMed
6) Dasgupta B, et al.:2012 Provisional classification criteria for polymyalgia rheumatica:a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012;64:943-954.
PubMed
7) Zhang W, et al.:European League Against Rheumatism recommendations for calcium pyrophosphate deposition. Part I:terminology and diagnosis. Ann Rheum Dis 2011;70:563-570.
PubMed
8) Eshed I, et al.:Tenosynovitis of the flexor tendons of the hand detected by MRI:an early indicator of rheumatoid arthritis. Rheumatology(Oxford) 2009;48:887-891.
PubMed
9) Wiesman IM, et al.:Sensitivity and specificity of clinical testing for carpal tunnel syndrome. Can J Plast Surg 2003;11:70-72.
PubMed
10) Zhang D, et al.:Accuracy of Provocative Tests for Carpal Tunnel Syndrome. J Hand Surg Glob Online 2020;2:121-125.
PubMed
11) Bookman A, et al.:The wrist and hand. In:Lawry GV, et al., eds.:Fam's Musculoskeletal Examination and Joint Injection Techniques, 2nd ed. Mosby Elsevier 2010:29-43.
 
P.80 掲載の参考文献
1) Fujii T, Matsudaira K:Prevalence of low back pain and factors associated with chronic disabling back pain in Japan. Eur Spine J 2013;22:432-438.
PubMed
2) Noriko Y, et al.:Prevalence of knee pain, lumbar pain and its coexistence in Japanese men and women:The Longitudinal Cohorts of Motor System Organ (LOCOMO) study. J Bone Miner Metab 2014;32:524-532.
 
3) 日本整形外科学会/日本腰痛学会 監, 日本整形外科学会診療ガイドライン委員会/腰痛診療ガイドライン策定委員会 編:腰痛診療ガイドライン2019, 改訂第2版. 南山堂, 2019.
 
4) Deyo RA, et al.:Low back pain. N Engl J Med 2001;344:363-370.
PubMed
5) 日本整形外科学会/日本腰痛学会 監, 日本整形外科学会診療ガイドライン委員会/腰痛診療ガイドライン策定委員会 編:腰痛診療ガイドライン2012. 南山堂, 2012.
 
6) Suzuki H, et al.:Diagnosis and Characters of Non-Specific Low Back Pain in Japan:The Yamaguchi Low Back Pain Study. PLoS One 2016;11:e0160454.
PubMed
7) 安藤哲朗:脊髄円錐上部症候群, 脊髄円錐部症候群. 脊椎脊髄ジャーナル 2015;28:185-190.
 
8) Calin A, et al.:Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613-2614.
PubMed
9) Rudwaleit M, et al.:Inflammatory back pain in ankylosing spondylitis:a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569-578.
PubMed
10) Sieper J, et al.:New criteria for inflammatory back pain in patients with chronic back pain:a real patient exercise by experts from the Assessment of SpondyloArthritis international Society(ASAS). Ann Rheum Dis 2009;68:784-788.
PubMed
11) Zimmerli W:Clinical practice. Vertebral osteomyelitis. N Engl J Med 2010;362:1022-1029.
PubMed
12) Mylona E, et al.:Pyogenic vertebral osteomyelitis:a systematic review of clinical characteristics. Semin Arthritis Rheum 2009;39:10-17.
PubMed
13) Helliwell PS:Axial disease in psoriatic arthritis. Rheumatology(Oxford) 2020;59:1193-1195.
PubMed
P.88 掲載の参考文献
1) Wilson JJ, Furukawa M:Evaluation of the patient with hip pain. Am Fam Physician 2014;89:27-34.
PubMed
P.96 掲載の参考文献
1) Margaretten ME, et al.:Does this adult patient have septic arthritis? JAMA 2007;297:1478-1488.
PubMed
Huddleston JI, et al.:Hip and Knee Pain. In:Firestein GS, et al., eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2020:776-791.
 
Covey JC, et al.:Approach to the adult with unspecified knee pain. UpToDate, 2020. https://www.uptodate.com/contents/approach-to-the-adult-with-unspecified-knee-pain(2023年5月閲覧)
 
P.102 掲載の参考文献
1) 三好雄二, 他:足首・足・足趾. medicina 2017;54:2198-2203.
 
2) Stephen DJG, et al.:The Ankle and Foot. In:Lawry G, et al., eds.:Fam's Musculoskeletal Examination and Joint Injection Techniques, 2nd ed. Elsevier, 2010:89-101.
 
3) England BR, et al.:Clinical Features of Rheumatoid Arthritis. In:Firestein GS, et al., eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2020:1236-1257.
 
Chiodo CP, et al.:Foot and Ankle Pain:In:Firestein GS, et al., eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2020:792-799.
 
P.117 掲載の参考文献
1) 衞藤義勝:Fabry病の臨床:最近の治療. 日内科会誌 2009;98:875-882.
 
2) Katabathina VS, et al.:" Biliary Diseases with Pancreatic Counterparts":Cross-sectional Imaging Findings. Radio Graphics 2016;2:374-392(375).
 
3) Schmidt T, et al.:Clinical, radiographic and biochemical characteristics ofadult hypophosphatasia. Osteoporos Int 2017;28:2653-2662.
 
4) UpToDate(R) 原発性副甲状腺機能亢進症
 
5) Reddy SM, et al.:Real-world effectiveness of anti-TNF switching in psoriatic arthritis:a systematic review of the literature. Clin Rheumatol 2016;35:3081-3087.
 
6) Minisola S, et al.:Tumour-induced osteomalacia. Nat Rev Dis Primers 2017;3:17044.
PubMed
7) Hidaka N, et al.:Clinical Challenges in Diagnosis, Tumor Localization and Treatment of Tumor-Induced Osteomalacia:Outcome of a Retrospective Surveillance. J Bone Miner Res 2022;37:1479-1488.
PubMed
8) Hall AM, et al.:Drug-induced renal Fanconi syndrome. Q J Med 2014;107:261-269.
 
9) 田中一郎, ほか:わが国における後天性凝固因子インヒビターの実態に関する3年間の継続調査-予後因子に関する検討-. 日本血栓止血学会誌2008;19:140-153.
 
P.127 掲載の参考文献
1) Smith JR, et al.:Management of uveitis:a rheumatologic perspective. Arthritis Rheum 2002;46:309-318.
PubMed
2) Lutt JR, et al.:Orbital inflammatory disease. Semin Arthritis Rheum 2008;37:207-222.
PubMed
3) Dana R:Clinical manifestations and diagnosis of scleritis. UpToDate. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-scleritis(2021年7月22日閲覧)
 
4) Gu J, et al.:Necrotizing scleritis and peripheral ulcerative keratitis associated with Wegener's granulomatosis. Ophthalmol Ther 2013;2:99-111.
PubMed
5) Rosenbaum JT, et al.:The Eyes Have it:A Rheumatologist's View of Uveitis. Arthritis Rheumatol 2018;70:1533-1543.
PubMed
6) 日本眼炎症学会ぶどう膜炎診療ガイドライン作成委員会:ぶどう膜炎診療ガイドライン. 日眼会誌 2019;123:635-696.
 
7) ベーチェット病眼病変診療ガイドライン作成委員会:Behcet病(ベーチェット病)眼病変診療ガイドライン. 日眼会誌 2012;116:394-426. https://www.nichigan.or.jp/member/journal/guideline/detail.html?itemid=290&dispmid=909(2022年4月閲覧)
 
8) Biousse V, et al.:Ischemic optic neuropathies. N Engl J Med 2015;372:2428-2436.
PubMed
9) Singh AG, et al.:Visual manifestations in giant cell arteritis:trend over 5 decades in a population-based cohort. J Rheumatol 2015;42:309-315.
 
10) Liu GT, et al.:Visual morbidity in giant cell arteritis. Clinical characteristics and prognosis for vision. Ophthalmology 1994;101:1779-1785.
PubMed
11) Hayreh SS, et al.:Occult giant cell arteritis:ocular manifestations. Am J Ophthalmol 1998;125:521-526.
PubMed
12) Andrew NH, et al.:An analysis of IgG4-related disease (IgG4-RD) among idiopathic orbital inflammations and benign lymphoid hyperplasias using two consensus-based diagnostic criteria for IgG4-RD. Br J Ophthalmol 2015;99:376-381.
PubMed
13) Aristodemou P, et al.:Therapy insight:The recognition and treatment of retinal manifestations of systemic vasculitis. Nat Clin Pract Rheumatol 2006;2:443-451.
PubMed
14) Wong K, et al.:Visual loss as the initial symptom of systemic lupus erythematosus. Am J Ophthalmol 1981;92:238-244.
 
P.138 掲載の参考文献
1) Chong BF, et al.:Skin Disease in Cutaneous Lupus Erythematosus. In:Wallace D, et al., eds.:Dubois' Lupus Erythematosus and Related Syndromes, 9th ed. Elsevier, 2018:395-406.
 
2) Sticherling M:Systemic sclerosis - the dermatological perspective. J Dtsch Dermatol Ges 2019;17:716-728.
PubMed
3) Franciosi E, et al.:Ovoid palatal patch:a clue to anti-TIF1γ dermatomyositis. BMJ Case Rep 2020;13:e234111.
 
4) Sobolewski P, et al.:Nail involvement in psoriatic arthritis. Reumatologia 2017;55:131-135.
PubMed
5) Micheletti RG, et al.:Cutaneous Manifestations of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Arthritis Rheumatol 2020;72:1741-1747.
PubMed
6) Schwartz RA, et al.:Erythema nodosum:a sign of systemic disease. Am Fam Physician 2007;75:695-700.
PubMed
7) Perez-Garza DM, et al.:A Practical Approach and Diagnostic Algorithm. Am J Clin Dermatol 2021;22:367-378.
PubMed
8) Mekkes JR, et al.:Causes, investigation and treatment of leg ulceration. Br J Dermatol 2003;148:388-401.
PubMed
9) Hartig F, et al.:Livedo Racemosa - The Pathophysiology of Decompression-Associated Cutis Marmorata and Right/Left Shunt. Front Physiol 2020;11:994.
PubMed
10) 北島康雄:皮疹の因数分解・ロジック診断-まぎらわしい炎症性の皮疹を絶対に見間違えない方法. 学研メディカル秀潤社, 2018.
 
11) 濱崎洋一郎:皮膚科医が診るSjogren 症候群. 日臨皮医誌 2016;33:483-491.
 
12) 上阪等:多発性筋炎・皮膚筋炎の病態・診断・治療. 日内会誌 2016;105:1789-1795.
 
P.151 掲載の参考文献
1) Gutsche M, et al.:Connective Tissue Disease-associated Interstitial Lung Disease:A review. Curr Respir Care Rep 2012;1:224-232.
PubMed
2) 日本呼吸器学会・日本リウマチ学会合同膠原病に伴う間質性肺疾患診断・治療指針2020 作成委員会 編:膠原病に伴う間質性肺疾患診断・治療指針2020. メディカルレビュー社, 2020.
 
3) Fischer A, et al.:An official European Respiratory Society/American Thoracic Society research statement:interstitial pneumonia with autoimmune features. Eur Respir J 2015;46:976-987.
PubMed
4) Mariette X, et al.:Primary Sjogren's Syndrome. N Engl J Med 2018;378:931-939.
PubMed
5) Flament T, et al.:Pulmonary manifestations of Sjogren's syndrome. Eur Respir Rev 2016;25:110-123.
PubMed
6) Betteridge Z, et al.:Myositis-specific autoantibodies:an important tool to support diagnosis of myositis. J Intern Med 2016;280:8-23.
PubMed
7) Sato S, et al.:Initial predictors of poor survival in myositis-associated interstitial lung disease:a multicentre cohort of 497 patients. Rheumatology (Oxford) 2018;57:1212-1221.
PubMed
8) Kurtzman DJB, et al.:Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis:A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol 2018;78:776-785.
PubMed
9) Tanizawa K, et al.:HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 2011;105:1380-1387.
PubMed
10) Tanizawa K, et al.:The prognostic value of HRCT in myositis-associated interstitial lung disease. Respir Med 2013;107:745-752.
PubMed
11) Kuwana M:Circulating Anti-Nuclear Antibodies in Systemic Sclerosis:Utility in Diagnosis and Disease Subsetting. J Nippon Med Sch 2017;84:56-63.
PubMed
12) Ozaki S, et al.:Severity-based treatment for Japanese patients with MPO-ANCA-associated vasculitis:the JMAAV study. Mod Rheumatol 2012;22:394-404.
PubMed
13) Krause ML, et al.:Update on diffuse alveolar hemorrhage and pulmonary vasculitis. Immunol Allergy Clin North Am 2012;32:587-600.
PubMed
P.156 掲載の参考文献
1) Feller-Kopman D, et al.:Pleural Disease. N Engl J Med 2018;378:740-751.
PubMed
2) Porcel JM, et al.:Classic, abbreviated, and modifiend Light's criteria:the end of the story? Chest. 1999;116;1833-1836.
 
3) Light RW 著, 家城隆次, 他 監訳:胸膜疾患のすべて, 改訂第3版. 診断と治療社, 2015(Light RW:Pleural Diseases, 6th ed. Wolters Kluwer Health/Lippincott Williams & Wilkins, 2013).
 
4) Walker WC, et al.:Rheumatoid pleuritis. Ann Rheum Dis 1967;26:467-474.
PubMed
5) Aggarwal AN, et al.:Meta-analysis of Indian studies evaluating adenosine deaminase for diagnosing tuberculous pleural effusion. Int J Tuberc Lung Dis 2016;20:1386-1391.
PubMed
6) Choi BY, et al.:Characteristics of pleural effusions in systemic lupus erythematosus:differential diagnosis of lupus pleuritis. Lupus 2015;24:321-326.
PubMed
7) Suzuki E, et al.:Primary Sjogren's Syndrome Accompanied by Clinical Features of TAFRO Syndrome. Case Rep Rheumatol 2020;2020:8872774.
PubMed
P.163 掲載の参考文献
1) 坂井建雄. 腎臓のはなし-130グラムの臓器の大きな役割(中公新書). 中央公論新社, 2013:v-204.
 
2) Hoenig MP, et al.:Overview of Kidney Structure and Function. In:Gilbert SJ, et al., eds.:National Kidney Foundation Primer on Kidney Diseases, 7th ed. Elsevier, 2018:2-18.
 
3) 坂井建雄, 他 総編集:腎・泌尿器(カラー図解 人体の正常構造と機能 V), 改訂第4版. 日本医事新報社, 2021:89.
 
4) Anders HJ, et al.:Renal co-morbidity in patients with rheumatic diseases. Arthritis Res Ther 2011;13:222.
 
5) 厚生労働省難治性疾患克服研究事業進行性腎障害に関する調査研究班 難治性ネフローゼ症候群分科会:ネフローゼ症候群診療指針. 日腎会誌 2011;53:78-122.
 
6) Thomas B:The kidneys and rheumatic diseases. In:Hochberg MC, et al., eds.:Rheumatology, 7th ed. Elsevier, 2019:305-316.
 
7) Hiremath S, et al.:History and physical diagnosis. In:Lerma EV, et al., eds.:Nephrology Secrets, 4th ed. Elsevier, 2019:1-8.
 
8) 出村豊, 他:エコーで腎臓を測る. 臨検 2019;63:1324-1330.
 
P.164 掲載の参考文献
1) Yatim KM, et al.:A brief journey through the immune system. Clin J Am Soc Nephrol 2015;10:1274-1281.
PubMed
2) Mathern DR, et al.:Molecules Great and Small:The Complement System. Clin J Am Soc Nephrol 2015;10:1636-1650.
PubMed
P.171 掲載の参考文献
1) 志水英明:尿で何がわかるの? 鈴木利彦 監, 坂井正弘 編:「型」が身につく蛋白尿・血尿の診かた・考えかた. 日本医事新報社, 2021:62-66.
 
2) 高野敬佑:血尿がある場合の鑑別の進め方は? 鈴木利彦 監, 坂井正弘 編:「型」が身につく蛋白尿・血尿の診かた・考えかた. 日本医事新報社, 2021:174-184.
 
3) Endre ZH, et al.:Clearance and beyond:the complementary roles of GFR measurement and injury biomarkers in acute kidney injury (AKI). Am J Physiol Renal Physiol 2011;301:F697-F707.
PubMed
4) AKI(急性腎障害)診療ガイドライン作成委員会 編:AKI(急性腎症)診療ガイドライン2016. 日腎会誌 2017;59:419-533. https://cdn.jsn.or.jp/guideline/pdf/419-533.pdf(2022年4月閲覧)
 
5) Fatehi P, et al.:Evaluation of acute kidney injury among hospitalized adult patients. UpToDate, 2022. https://www.uptodate.com/contents/evaluation-of-acute-kidney-injury-among-hospitalized-adult-patients?topicRef=7188&source=see_link(2022年4月閲覧)
 
6) Santacruz JC, et al.:Lupus Cystitis, From Myth to Reality:A Narrative Review. Cureus 2021;13:e20409.
PubMed
7) Bichet DG:Evaluation of patients with polyuria. UpToDate, 2021. https://www.uptodate.com/contents/evaluation-of-patients-with-polyuria(2022年4月閲覧)
 
P.172 掲載の参考文献
1) Sterns RH, et al.:Treating profound hyponatremia:a strategy for controlled correction. Am J Kidney Dis 2010;56:774-779.
PubMed
P.179 掲載の参考文献
1) Shane A, et al.:Glomerular Clinicopathologic Syndromes. In:Gilbert SJ, et al., eds.:National Kidney Foundation Primer on Kidney Diseases, 8th ed. Elsevier, 2022:164-175.
 
2) Yokoyama H, et al.:Membranous nephropathy in Japan:analysis of the Japan Renal Biopsy Registry(J-RBR). Clin Exp Nephrol 2012;16:557-563.
PubMed
3) 成田一衛 監, 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)難治性腎障害に関する調査研究班 編:エビデンスに基づくネフローゼ症候群診療ガイドライン2020. 東京医学社, 2020.
 
4) Meyrier A, et al.:Acute kidney injury(AKI) in minimal change and other forms of nephrotic syndrome 2022. UpToDate 2022. https://www.uptodate.com/contents/acute-kidney-injury-aki-in-minimal-change-disease-and-other-forms-ofnephrotic-syndrome(2022年8月閲覧)
 
5) 丸山彰一:腎炎・ネフローゼの病態と治療. 日内会誌 2019;108:535-539.
 
6) American Diabetes Association:Microvascular Complications and Foot Care:Standards of Medical Care in Diabetes-2021. Diabetes Care 2021;44(Suppl 1):S151-S167.
 
7) 日本腎臓学会 編:CKD診療ガイド2012. 東京医学社, 2012.
 
P.187 掲載の参考文献
1) 加藤規利, 他:aHUS の病態と臨床. 日血栓止血会誌 2020;31:45-54.
 
2) Laurence J, et al.:Atypical hemolytic uremic syndrome(aHUS):essential aspects of an accurate diagnosis. Clin Adv Hematol Oncol 2016;14(Suppl 11):2-15.
 
3) 宮川義隆:血栓性血小板減少性紫斑病(TTP)に対する分子標的治療. 日血栓止血会誌 2020;31:28-36.
 
4) James NG, et al.:Diagnostic approach to suspected TTP, HUS, or other thrombotic microangiopathy (TMA). UpToDate 2021. https://www.uptodate.com/contents/diagnostic-approach-to-suspected-ttp-hus-or-other-thrombotic-microangiopathy-tma(2022年8月閲覧)
 
5) Ursula C, et al.:Acute Interstitial Nephritis. In:Gilbert SJ, et al., eds.:National Kidney Foundation Primer on Kidney Diseases, 8th ed. Elsevier, 2022:325-330.
 
6) Montrief T, et al.:Scleroderma renal crisis:a review for emergency physicians. Intern Emerg Med 2019;14:561-570.
PubMed
7) Praga M, et al.:Clinical manifestations and diagnosis of acute interstitial nephritis. UpToDate 2022. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-acute-interstitial-nephritis(2022年8月閲覧)
 
8) 志水英明:日常診療で役立つNa-Clを用いた酸塩基平衡異常の鑑別と注意点. 日内会誌 2022;111:957-964.
 
9) Adomako EA, et al.:Idiopathic Hypokalemia in Lupus Nephritis:A Newly Recognized Entity. Kidney360 2021;2:1553-1539.
PubMed
10) Gornik HL, et al.:First International Consensus on the diagnosis and management of fibromuscular dysplasia. Vasc Med 2019;24:164-189.
PubMed
11) Shane A. et al.:Glomerular Clinicopathologic Syndromes. In:Gilbert SJ, et al., eds.:National Kidney Foundation Primer on Kidney Diseases, 8th ed. Elsevier, 2022:164-175.
 
12) 前嶋明人:レジデントのための腎臓教室-ベストティーチャーに教わる全14章. 日本医事新報社, 2017.
 
P.195 掲載の参考文献
1) Galie N, et al.:2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension:The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology(ESC)and the European Respiratory Society(ERS):Endorsed by:Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation(ISHLT). Eur Heart J 2016;37:67-119.
 
2) Simonneau G, et al.:Haemodynamic definitions and updated clinical classification of pulmonary hypertension. Eur Respir J 2019;53:1801913.
PubMed
3) 福田恵一, 他:肺高血圧症治療ガイドライン(2017年改訂版). 日本循環器学会, 2018. https://www.j-circ.or.jp/cms/wp-content/uploads/2017/10/JCS2017_fukuda_h.pdf(2021年12月閲覧)
 
P.201 掲載の参考文献
1) Peebles CR, et al.:Pericardial disease--anatomy and function. Br J Radiol 2011;84(Spec Iss 3):S324-S337.
 
2) Spodick DH:Pericardial disease in the vasculitis-connective tissue disease group. In:The Pericardium. A comprehensive textbook. Marcel Dekker, 1997:314-333.
 
3) Knockaert DC, et al.:Cardiac involvement in systemic inflammatory diseases. Eur Heart J 2007;28:1797-1804.
PubMed
4) Kimoto M, et al.:Lupus and the Cardiopulmonary System. In:Wallace DJ, et al., eds.:Dubois' Lupus Erythematosus & Related Syndromes, 9th ed. Elsevier, 2018:418-433.
 
P.210 掲載の参考文献
1) Di Filippo M, et al.:Infliximab monotherapy for neuro-Behcet's disease:a case report. J Neurol Sci 2014;347:389-390.
PubMed
2) Katsumata Y, et al.:Diagnostic reliability of magnetic resonance imaging for central nervous system syndromes in systemic lupus erythematosus:a prospective cohort study. BMC Musculoskelet Disord 2010;11:13.
PubMed
3) 伊藤悟:感染性脳炎と非感染性脳炎. 神経治療 2017;34:215-218.
Medical*Online
4) 深浦彦彰:脱髄疾患:臨床症状と診断. 神経治療 2018;35:478-483.
Medical*Online
5) Hirohata S, et al.:Accuracy of cerebrospinal fluid IL-6 testing for diagnosis of lupus psychosis. A multicenter retrospective study. Clin Rheumatol 2009;28:1319-1323.
PubMed
6) 日本ベーチェット病学会 監修, 厚生労働科学研究費補助金(難治性疾患政策研究事業)ベーチェット病に関する調査研究班, 他 編, 水木信久, 他 責任編集:ベーチェット病診療ガイドライン2020. 診断と治療社, 2020.
 
7) Bertsias GK, et al.:Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. Nat Rev Rheumatol 2010;6:358-367.
PubMed
8) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
PubMed
9) Govoni M, et al.:The management of neuropsychiatric lupus in the 21st century:still so many unmet needs? Rheumatology (Oxford) 2020;59 (Suppl 5):v52-v62.
 
10) Schwartz N, et al.:Neuropsychiatric lupus:new mechanistic insights and future treatment directions. Nat Rev Rheumatol 2019;15:137-152.
PubMed
11) Hanly JG, et al.:Review:Nervous System Disease in Systemic Lupus Erythematosus:Current Status and Future Directions. Arthritis Rheumatol 2019;71:33-42.
PubMed
12) Tokunaga M, et al.:Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-475.
PubMed
13) 日本神経学会 監, 「多発性硬化症・視神経脊髄炎診療ガイドライン」作成委員会 編:多発性硬化症・視神経脊髄炎診療ガイドライン2017. 医学書院, 2017. https://www.neurology-jp.org/guidelinem/koukasyo_onm_2017.html(2022年6月10日閲覧)
 
14) De Virgilio A, et al.:Idiopathic hypertrophic pachymeningitis:an autoimmune IgG4-related disease. Immunol Res 2017;65:386-394.
PubMed
15) Gray JD, et al.:Genomic and epigenomic mechanisms of glucocorticoids in the brain. Nat Rev Endocrinol 2017;13:661-673.
PubMed
16) Ciriaco M, et al.:Corticosteroid-related central nervous system side effects. Pharmacol Pharmacother 2013;4:S94-S98.
PubMed
17) 望月仁志, 他:薬剤性脳症. 日内会誌 2017;106:1579-1583.
 
18) Fugate JE, et al.:Posterior reversible encephalopathy syndrome:associated clinical and radiologic findings. Mayo Clin Proc 2010;85:427-432.
PubMed
P.218 掲載の参考文献
1) Amato AA, et al.:Sensory Ganglionopathy. N Engl J Med 2020;383:1657-1662.
PubMed
2) Mori K, et al.:Spinal cord magnetic resonance imaging demonstrates sensory neuronal involvement and clinical severity in neuronopathy associated with Sjogren's syndrome. J Neurol Neurosurg Psychiatry 2001;71:488-492.
PubMed
3) Sene D:Small fiber neuropathy:Diagnosis, causes, and treatment. Joint Bone Spine 2018;85:553-559.
PubMed
4) Nathani D, et al.:Nerve biopsy:Current indications and decision tools. Muscle Nerve 2021;64:125-139.
PubMed
5) 神田隆:血管炎に伴うニューロパチー. 日内会誌 2019;108:1517-1523.
 
6) Gwathmey KG, et al.:Vasculitic neuropathies. Lancet Neurol 2014;13:67-82.
PubMed
7) The American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608.
PubMed
8) West SG, et al.:Lupus and the nervous system:clinical aspects, psychopathology, and imaging. In:Wallace DJ, et al., eds.:Dubois' Lupus Erythematosus and Related Syndromes, 9th ed. Elsevier, 2018:36, 434-456.
 
9) Margaretten M:Neurologic Manifestations of Primary Sjogren Syndrome. Rheum Dis Clin North Am 2017;43:519-529.
PubMed
10) Jamilloux Y, et al.:Immunological profiles determine neurological involvement in Sjogren's syndrome. Eur J Intern Med 2014;25:177-181.
PubMed
11) 古賀道明:サルコイドニューロパチー. Brain Nerve 2014;66:981-985.
 
12) Oaklander AL, et al.:Scientific Advances in and Clinical Approaches to Small-Fiber Polyneuropathy:A Review. JAMA Neurol 2019;76:1240-1251.
PubMed
13) Imamura M, et al.:Ganglionic Acetylcholine Receptor Antibodies and Autonomic Dysfunction in Autoimmune Rheumatic Diseases. Int J Mol Sci 2020;21:1332.
PubMed
P.224 掲載の参考文献
1) Weisman MH:Digestive and Hepatic Aspects of the Rheumatic Diseases. Rheum Dis Clin North Am 2018;44:xiii-xiv.
PubMed
2) Halabi H, et al.:Gastrointestinal Manifestations of Rheumatic Diseases. In:Almoallim H, et al., eds.:Skills in Rheumatology. Springer, 2021:475-499.
 
3) Denton CP, et al.:Systemic sclerosis. Lancet 2017;390:1685-1699.
PubMed
4) Ebert EC, et al.:Gastrointestinal and hepatic manifestations of systemic lupus erythematosus. J Clin Gastroenterol 2011;45:436-441.
PubMed
5) Skef W, et al.:Gastrointestinal Behcet's disease:a review. World J Gastroenterol. 2015;21:3801-3812.
PubMed
6) Messer J, et al.:Association of adrenocorticosteroid therapy and peptic-ulcer disease. N Engl J Med 1983;309:21-24.
PubMed
7) Piper JM, et al.:Corticosteroid use and peptic ulcer disease:role of nonsteroidal anti-inflammatory drugs. Ann Intern Med 1991;114:735-740.
PubMed
8) 日本消化器病学会 編:消化性潰瘍診療ガイドライン2015, 改訂第2版. 南江堂, 2015:156.
 
P.231 掲載の参考文献
1) Fijten GH, et al.:Unexplained lymphadenopathy in family practice. An evaluation of the probability of malignant causes and the effectiveness of physicians' workup. J Fam Pract 1988;27:373-376.
PubMed
2) Gaddry HL, et al.:Unexplained Lymphadenopathy:Evaluation and Differential Diagnosis. Am Fam Physician 2016;94:896-903.
 
3) Chau I, et al.:Rapid access multidisciplinary lymph node diagnostic clinic:analysis of 550 patients. Br J Cancer 2003;88:354-361.
PubMed
P.239 掲載の参考文献
1) Petersdorf RG, et al.:Fever of unexplained origin:report on 100 cases. Medicine (Baltimore) 1961;40:1-30.
PubMed
2) Durack DT, et al.:Fever of unknown origin--reexamined and redefined. Curr Clin Top Infect Dis 1991;11:35-51.
PubMed
3) Arnow PM, et al.:Fever of unknown origin. Lancet 1997;350:575-580.
PubMed
4) Mourad O, et al.:A comprehensive evidence-based approach to fever of unknown origin. Arch Intern Med 2003;163:545-551.
PubMed
5) Vanderschueren S, et al.:From prolonged febrile illness to fever of unknown origin. Arch Intern Med 2003;163:1033-1041.
PubMed
6) Hellmann DB:Giant Cell Arteritis, Polymyalgia Rheumatica, and Takayasu's Arteritis. In:Firestein GS, et al., eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2021:1595-1616.
 
7) Knockaert DC, et al.:Fever of unknown origin in elderly patients. J Am Geriatr Soc 1993;41:1187-1192.
PubMed
P.240 掲載の参考文献
1) Solis-Herruzo JA, et al.:Laparoscopy in fever of unknown origin-study of seventy cases. Endoscopy 1981;13:207-210.
PubMed
2) Takahashi T, et al.:Diagnostic laparotomy in fever of unknown origin. Rev Invest Clin 1991;43:25-30.
PubMed
3) Schonau V, et al.:The value of 18 F-FDG-PET/CT in identifying the cause of fever of unknown origin (FUO) and inflammation of unknown origin (IUO):data from a prospective study. Ann Rheum Dis 2018;77:70-77.
PubMed
P.249 掲載の参考文献
1) Peng SL, et al.:Anti-nuclear antibodies. In:Firestein GS, et al., eds.:Firestein & Kelly's textbook of rheumatology, 11th ed. Elsevier, 2021:875-889.
 
2) Bossuyt X, et al.:Understanding and interpreting antinuclear antibody tests in systemic rheumatic diseases. Nat Rev Rheumatol 2020;16:715-726.
PubMed
3) Nakazawa D, et al.:Pathogenesis and therapeutic interventions for ANCA-associated vasculitis. Nat Rev Rheumatol 2019;15:91-101.
PubMed
4) Luqmani RA:Antineutrophil cytoplasm antibody-associated vasculitis. In:Hochberg MC, et al. eds.:Rheumatology, 7th ed. Elsevier, 2018:1368-1377.
 
5) Roozendaal C, et al.:Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)? Clin Exp Immunol 1999;116:206-213.
PubMed
6) Bosch X, et al.:Antineutrophil cytoplasmic antibodies. Lancet 2006;368:404-418.
PubMed
7) Shmerling RH, et al.:The rheumatoid factor:an analysis of clinical utility. Am J Med 1991;91:528-534.
PubMed
8) Nielen MM, et al.:Specific autoantibodies precede the symptoms of rheumatoid arthritis:a study of serial measurements in blood donors. Arthritis Rheum 2004;50:380-386.
PubMed
9) Sokolove J, et al.:Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheum 2014;66:813-821.
 
10) Aggarwal R, et al.:Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 2009;61:1472-1483.
PubMed
P.260 掲載の参考文献
1) Tani Y, et al.:Comparison of albuminuria test and urine test strip in Japanese hypertensive patients:AVA-E study. Clin Nephrol 2015;84:270-273.
PubMed
2) Stefanovic V, et al.:Beta2-microglobulin and alpha1-microglobulin as markers of Balkan endemic nephropathy, a worldwide disease. Ren Fail 2011;33:176-183.
PubMed
3) 湯澤由紀夫:尿中NAG, 尿中b2ミクログロブリン-尿細管障害・AKIとバイオマーカー. 日内会誌 2008;97:971-978.
 
4) Krishnan A, et al.:Laboratory Assessment of Kidney Disease:Glomerular Filtration Rate, Urinalysis, and Proteinuria. In:Chertow G, et al., eds.:Brenner and Rector's The Kidney, 11th ed. Elsevier, 2019:733-757.
 
5) 日本腎臓学会 編:エビデンスに基づくCKD診療ガイドライン2018. 東京医学社, 2018.
 
6) 成田一衛 監, 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)難治性腎障害に関する調査研究班 編:エビデンスに基づくネフローゼ症候群診療ガイドライン2020. 東京医学社, 2020. https://jsn.or.jp/academicinfo/report/evidence_nephrotic_guideline2020.pdf(2022年9月閲覧)
 
P.268 掲載の参考文献
1) Krishnan A, et al.:Laboratory Assessment of Kidney Disease:Glomerular Filtration Rate, Urinalysis, and Proteinuria. In:Chertow C, et al., eds.:Brenner and Rector's The Kidney, 11th ed. Elsevier, 2019:733-757.
 
2) 血尿診断ガイドライン編集委員会 編:血尿診断ガイドライン2013. ライフサイエンス出版, 2013.
 
3) Kohler H, et al.:Acanthocyturia-a characteristic marker for glomerular bleeding. Kidney Int 1991;40:115-120.
PubMed
4) 上田尚彦, 今井宣子:尿沈渣 標本の作成から診断まで 改訂第2版, 診断と治療社, 2007.
 
5) 成田一衛 監, 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)難治性腎障害に関する調査研究班 編:エビデンスに基づくネフローゼ症候群診療ガイドライン2020. 東京医学社, 2020. https://jsn.or.jp/academicinfo/report/evidence_nephrotic_guideline2020.pdf(2022年9月閲覧)
 
6) Wald R, et al.:Interobserver reliability of urine sediment interpretation. Clin J Am Soc Nephrol 2009;4:567-571.
PubMed
P.274 掲載の参考文献
1) Botev R, et al.:Estimating glomerular filtration rate:Cockcroft-Gault and Modification of Diet in Renal Disease formulas compared to renal inulin clearance. Clin J Am Soc Nephrol 2009;4:899-906.
PubMed
2) Kellum JA, et al.:KDIGO Clinical Practice Guideline for Acute Kidney Injury. Kidney Int Suppl 2012;2:1-138. https://kdigo.org/wp-content/uploads/2016/10/KDIGO-2012-AKI-Guideline-English.pdf(2022年9月閲覧)
 
3) Moran SM, et al.:Course of acute renal failure studied by a model of creatinine kinetics. Kidney Int 1985;27:928-937.
 
Krishnan A, et al.:Laboratory Assessment of Kidney Disease:Glomerular Filtration Rate, Urinalysis, and Proteinuria. In:Chertow G, et al., eds.:Brenner and Rector's The Kidney, 11th ed. Elsevier, 2019:732-742.
 
P.288 掲載の参考文献
1) Strickland C:Radiographic and imaging modalities. Sterling GW, et al., eds.:Rheumatology Secrets, 4th ed. Elsevier, 2019:68-81.
 
2) Zhang W, et al.:EULAR evidence-based recommendations for the diagnosis of hand osteoarthritis:report of a task force of ESCISIT. Ann Rheum Dis 2009;68:8-17.
PubMed
3) Okuno H, et al.:Clinical features and radiological findings of 67 patients with SAPHO syndrome. Mod Rheumatol 2018;28:703-708.
PubMed
4) Weber U, et al.:Does spinal MRI add incremental diagnostic value to MRI of the sacroiliac joints alone in patients with non-radiographic axial spondyloarthritis? Ann Rheum Dis 2015;74:985-992.
PubMed
5) Bennett AN, et al.:Evaluation of the diagnostic utility of spinal magnetic resonance imaging in axial spondylarthritis. Arthritis Rheum 2009;60:1331-1341.
PubMed
6) Goerne H, et al.:Imaging of pulmonary hypertension:an update. Cardiovasc Diagn Ther 2018;8:279-296.
PubMed
7) Kermani TA, et al.:Extra-cranial giant cell arteritis and Takayasu arteritis:How similar are they? Semin Arthritis Rheum 2015;44:724-728.
PubMed
8) Sammel AM, et al.:Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis:A Prospective, Double-Blind, Cross-Sectional Study. Arthritis Rheumatol 2019;71:1319-1328.
PubMed
P.296 掲載の参考文献
1) Ahmed I, et al.:Safety of arthrocentesis and joint injection in patients receiving anticoagulation at therapeutic levels. Am J Med 2012;125:265-269.
PubMed
2) Yui JC, et al.:Arthrocentesis and joint injection in patients receiving direct oral anticoagulants. Mayo Clin Proc 2017;92:1223-1226.
PubMed
3) Hermans J, et al.:The most accurate approach for intra-articular needle placement in the knee joint:a systematic review. Semin Arthritis Rheum 2011;41:106-115.
PubMed
4) Petersen SK, et al.:Low frequency of septic arthritis after arthrocentesis and intra-articular glucocorticoid injection. Scand J Rheumatol. 2019;48:393-397.
PubMed
5) Uson J, et al.:EULAR recommendations for intra-articular therapies. Ann Rheum Dis 2021;80:1299-1305.
PubMed
6) Sholter DE, et al.:Synovial fluid analysis. UpToDate, 2021. https://www.uptodate.com/contents/synovial-fluid-analysis(2022年2月閲覧)
 
P.300 掲載の参考文献
1) 日本腎臓学会 編:腎生検ガイドブック2020. 東京医学社, 2020.
 
2) Berden AE, et al.:Histopathologic classification of ANCAassociated glomerulonephritis. J Am Soc Nephrol 2010;21:1628-1636.
PubMed
3) 松尾清一, 他:急速進行性腎炎症候群の診療指針 第2版. 日腎会誌 2011;53:509-555.
 
4) Wakasugi D, et al.:Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement:an analysis of predictive measures. J Rheumatol 2012;39:79-85.
 
5) Hasegawa J, et al.:Clinical and pathological features of antineutrophil cytoplasmic antibody-associated vasculitis in patients with minor urinary abnormalities. Nephrology (Carlton) 2018;23:1007-1012.
PubMed
6) Mise K, et al.:Prognostic Value of Tubulointerstitial Lesions, Urinary N-Acetyl-b-d-Glucosaminidase, and Urinary b2-Microglobulin in Patients with Type 2 Diabetes and BiopsyProven Diabetic Nephropathy. Clin J Am Soc Nephrol 2016;11:593-601.
 
P.303 掲載の参考文献
1) Hogan JJ, et al.:The Native Kidney Biopsy:Update and Evidence for Best Practice. Clin J Am Soc Nephrol 2016;11:354-362.
PubMed
P.311 掲載の参考文献
1) Fanouriakis A, et al.:Update on the diagnosis and management of systemic lupus erythematosus. Ann Rheum Dis 2021;80:14-25.
PubMed
2) Walling HW, et al.:Cutaneous Lupus Erythematosus:Issues in Diagnosis and Treatment. Am J Clin Dermatol 2009;10:365-381.
PubMed
3) Aringer M, et al.:2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 2019;71:1400-1412.
PubMed
4) Touma Z, et al.:Differential Diagnosis and Disease Associations. In:Wallace D, et al., eds.:Dubois' Lupus Erythematosus and Related Syndromes, 9th ed. Elsevier, 2018:598-605.
 
5) 厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究(自己免疫班), 他 編:全身性エリテマトーデス診療ガイドライン2019. 南山堂, 2019.
 
P.319 掲載の参考文献
1) Hughes M, et al.:Raynaud phenomenon and digital ulcers in systemic sclerosis. Nat Rev Rheumatol 2020;16:208-221.
PubMed
2) Clements P, et al.:Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol 1995;22:1281-1285.
PubMed
3) Kuwana M:Circulating Anti-Nuclear Antibodies in Systemic Sclerosis:Utility in Diagnosis and Disease Subsetting. J Nippon Med Sch 2017;84:56-63.
PubMed
4) van den Hoogen F, et al.:2013 classification criteria for systemic sclerosis:an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-1755.
PubMed
5) 桑名正隆:強皮症の新たな治療概念. 臨リウマチ 2015;27:281-287.
 
P.332 掲載の参考文献
1) Bottai M, et al.:ACR/EULAR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups:a methodology report. RMD Open 2017;3:e000507.
PubMed
2) Marc C, et al.:Rheumatology. Elsevier;7th edition;1293-1305, 2018.
 
3) Sato S, et al.:Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 2005;52:1571-1576.
PubMed
4) 上阪等, 他:多発性筋炎/皮膚筋炎に関する研究. 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業) 自己免疫疾患に関する調査研究 平成26年度総括・分担研究報告書(研究代表者 住田孝之). 2015:26-69.
 
5) Betteridge Z, et al.:Myositis-specific autoantibodies:an important tool to support diagnosis of myositis. J Intern Med 2016;280:8-23.
PubMed
6) McHugh NJ, et al.:Autoantibodies in myositis. Nat Rev Rheumatol. 2018;14:290-302.
PubMed
7) Hanbo Yang, et al.:Identification of multiple cancer-associated myositis-specific autoantibodies in idiopathic inflammatory myopathies:a large longitudinal cohort study. Arthritis Research & Therapy 2017;19:259.
 
8) Bohan A, et al.:Polymyositis and dermatomyositis(first of two parts). N Engl J Med 1975;292:344-347.
PubMed
P.343 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業自己免疫疾患に関する調査研究班 編:シェーグレン症候群診療ガイドライン2017年版. 診断と治療社, 2017.
 
2) St. Clair EW, et al.:Sjogren's Syndrome. In:Firestein GS, et al., eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2021:1284-1306.e4.
 
3) Baer AN, et al.:Sjogren syndrome. In:Hochberg MC, et al. eds.:Rheumatology, 7th ed. Elsevier, 2018:1205-1220.
 
4) Shiboski CH, et al.:2016 American College of Rheumatology/European League Against Rheumatism Classification Criteria for Primary Sjogren's Syndrome:A Consensus and Data-Driven Methodology Involving Three International Patient Cohorts. Arthritis Rheumatol 2017;69:35-45.
PubMed
5) Peng SL, et al.:Anti-nuclear Antibodies. In:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2021:875-889.
 
6) Burmester EF, et al.:Laboratory tests in rheumatic disorders. In:Rheumatology, 7th ed. Elsevier, 2018:257-262.
 
7) Tsuboi H, et al.:Comparison of performance of the 2016 ACR-EULAR classification criteria for primary Sjogren's syndrome with other sets of criteria in Japanese patients. Ann Rheum Dis 2017;76:1980-1985.
PubMed
8) Fujibayashi T, et al.:Revised Japanese criteria for Sjogren's syndrome (1999):availability and validity. Mod Rheumatol 2004;14:425-434.
PubMed
9) Shiboski CH, et al.:2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjogren's syndrome:A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis 2017;76:9-16.
PubMed
10) Seror R, et al.:EULAR Sjogren's syndrome disease activity index:development of a consensus systemic disease activity index for primary Sjogren's syndrome. Ann Rheum Dis 2010;69:1103-1109.
PubMed
P.350 掲載の参考文献
1) 厚生労働科学研究費補助金難治性疾患等政策研究事業(難治性疾患政策研究事業)自己免疫疾患研究班混合性結合組織病分科会(分科会長 田中良哉) 編:MCTD(混合性結合組織病)診療ガイドライン2021. 南山堂, 2021.
 
2) Sharp GC, et al.:Mixed connective tissue disease--an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen(ENA). Am J Med 1972;52:148-159.
 
3) 難病情報センター:混合性結合組織病(指定難病52). https://www.nanbyou.or.jp/entry/264(2022年3月閲覧)
 
4) Richard MB:Mixed Connective Tissue Disease, Overlap Syndromes, and Undifferentiated Connective Tissue Disease. In:West S, et al. eds.:Rheumatology Secrets, 4th ed. Elsevier, 2021:185-189.
 
5) Graf J:Overlap Syndromes. In:Firestein GS, et al. eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2021:1569-1583. e4.
 
6) Fukuda K, et al.:Japanese Circulation Society and the Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group. Guidelines for the Treatment of Pulmonary Hypertension(JCS 2017/JPCPHS 2017). Circ J 2019;83:842-945.
 
7) 東條毅, 他:混合性結合組織病(MCTD)の生命予後調査. 厚生省特定疾患皮膚・混合性結合組織病調査研究班混合性結合組織病分科会 平成10年度研究報告書. 1999:7-10.
 
P.359 掲載の参考文献
1) Yamanaka H, et al.:Estimates of the prevalence of and current treatment practices for rheumatoid arthritis in Japan using reimbursement data from health insurance societies and the IORRA cohort (I). Mod Rheumatol 2014;24:33-40.
PubMed
2) 日本リウマチ友の会:2015年 リウマチ白書-リウマチ患者の実態<総合編>. 日本リウマチ友の会, 2015.
 
3) Aletaha D, et al.:2010 Rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010;62:2569-2581.
PubMed
4) Aletaha D, et al.:2010 rheumatoid arthritis classification criteria:an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2010;69:1580-1588.
PubMed
5) 第6章 関節リウマチ(2. 内科的治療法). 平成22年度リウマチ・アレルギー相談員養成研修会テキスト. 厚生労働省健康局疾病対策課, 2010:123-154.
 
6) D'Agostino MA, et al.:Scoring ultrasound synovitis in rheumatoid arthritis:a EULAR-OMERACT ultrasound taskforce-Part 1:definition and development of a standardised, consensus-based scoring system. RMD Open 2017;3:e000428.
PubMed
7) 日本リウマチ学会MTX診療ガイドライン策定小委員会 編:関節リウマチ治療におけるメトトレキサート(MTX)診療ガイドライン2016年改訂版. 羊土社, 2016.
 
8) 日本リウマチ学会 編:関節リウマチ診療ガイドライン2020. 診断と治療社, 2021:17.
 
Saag KG, et al.:American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-784.
PubMed
Smolem JS, et al.:Treating rheumatoid arthritis to target:recommendations of an international task force. Ann Rheum Dis 2010;69:631-637.
 
岸本暢将, 他 編著:関節リウマチの診かた, 考えかたver. 3. 中外医学社, 2018.
 
Meyer O, et al.:Anticitrullinated protein/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage. Ann Rheum Dis 2003;62:120-126.
PubMed
P.361 掲載の参考文献
1) Aggarwal R, et al.:Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis. Arthritis Rheum 2009;61:1472-1483.
PubMed
P.369 掲載の参考文献
1) Jennette JC, et al.:2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
 
2) Bossuyt X, et al.:Position paper:Revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017;13:683-692.
PubMed
3) Gornik HL, et al.:Aortitis. Circulation 2008;117:3039-3051.
PubMed
4) Furuta S, et al.:Comparison of phenotype and outcome in microscopic polyangiitis between Europe and Japan. J Rheumatol 2014;41:325-333.
PubMed
5) Watts R, et al.:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-227.
PubMed
6) 日本皮膚科学血管炎・血管障害診療ガイドライン改訂版作成委員会:日本皮膚科学会ガイドライン 血管炎・血管障害診療ガイドライン2016年改訂版. 日皮会誌 2017;127:299-415.
 
P.382 掲載の参考文献
1) Sunderkotter CH, et al.:Nomenclature of Cutaneous Vasculitis:Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol 2018;70:171-184.
 
2) Hellmann DB:Giant Cell Arteritis, Polymyalgia Rheumatica, and Takayasu's Arteritis. In:Firestein GS, et al., eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2021:1595-1616.
 
3) Koide K:Takayasu arteritis in Japan. Heart Vessels Suppl 1992;7:48-54.
PubMed
4) Wood PR:Large-vessel vasculitis:giant cell arteritis, Takayasu arteritis, and aortitis. In:Sterling GW, et al., eds.:Rheumatology Secrets, 4th ed. Elsevier, 2019:227-235.
 
5) 日本循環器学会, 他:血管炎症候群の診療ガイドライン(2017年改訂版). 日本循環器学会, 2017.
 
6) Watanabe Y, et al.:Current Clinical Features of New Patients With Takayasu Arteritis Observed From Cross-Country Research in Japan:Age and Sex Specificity. Circulation 2015;132:1701-1709.
PubMed
7) Kerr GS, et al.:Takayasu arteritis. Ann Intern Med 1994;120:919-929.
PubMed
8) Dejaco C, et al.:EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice. Ann Rheum Dis 2018;77:636-643.
PubMed
9) Barra L, et al.:Imaging modalities for the diagnosis and disease activity assessment of Takayasu's arteritis:A systematic review and meta-analysis. Autoimmun Rev 2018;17:175-187.
PubMed
10) Yamada I, et al.:Takayasu arteritis:evaluation of the thoracic aorta with CT angiography. Radiology 1998;209:103-109.
PubMed
11) Koster MJ, et al.:Large-vessel giant cell arteritis:diagnosis, monitoring and management. Rheumatology(Oxford) 2018;57(Suppl 2):ii32-ii42.
 
12) Narula N, et al.:Fibromuscular Dysplasia:Contemporary Concepts and Future Directions. Prog Cardiovasc Dis 2018;60:580-585.
PubMed
13) Kobayashi S, et al.:Clinical and epidemiologic analysis of giant cell(temporal) arteritis from a nationwide survey in 1998 in Japan:the first government-supported nationwide survey. Arthritis Rheum 2003;49:594-598.
PubMed
14) Nuenninghoff DM, et al.:Incidence and predictors of large-artery complication(aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis:a population-based study over 50 years. Arthritis Rheum 2003;48:3522-3531.
PubMed
15) Imai N, et al.:Giant cell arteritis:clinical features of patients visiting a headache clinic in Japan. Intern Med 2011;50:1679-1682.
PubMed
16) Kobayashi S, et al.:Clinical and epidemiologic analysis of giant cell(temporal) arteritis from a nationwide survey in 1998 in Japan:the first government-supported nationwide survey. Arthritis Rheum 2003;49:594-598.
PubMed
17) Muratore F, et al.:Large-vessel giant cell arteritis:a cohort study. Rheumatology(Oxford) 2015;54:463-470.
PubMed
18) van der Geest KSM, et al.:Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis:A Systematic Review and Meta-analysis. JAMA Intern Med 2020;180:1295-1304.
PubMed
19) Kermani TA, et al.:Utility of erythrocyte sedimentation rate and C-reactive protein for the diagnosis of giant cell arteritis. Semin Arthritis Rheum 2012;41:866-871.
 
20) Hayreh SS, et al.:Giant cell arteritis:validity and reliability of various diagnostic criteria. Am J Ophthalmol 1997;123:285-296.
PubMed
21) Schmidt WA:Ultrasound in the diagnosis and management of giant cell arteritis. Rheumatology(Oxford) 2018;57(Suppl 2):ii22-ii31.
 
22) Hop H, et al.:Diagnostic value of axillary artery ultrasound in patients with suspected giant cell arteritis. Rheumatology (Oxford) 2020;59:3676-3684.
PubMed
23) Prieto-Gonzalez S, et al.:Large vessel involvement in biopsy-proven giant cell arteritis:prospective study in 40 newly diagnosed patients using CT angiography. Ann Rheum Dis 2012;71:1170-1176.
PubMed
24) Sammel AM, et al.:Diagnostic Accuracy of Positron Emission Tomography/Computed Tomography of the Head, Neck, and Chest for Giant Cell Arteritis:A Prospective, Double-Blind, Cross-Sectional Study. Arthritis Rheumatol 2019;71:1319-1328.
PubMed
25) Kermani TA, et al.:Large-vessel involvement in giant cell arteritis:a population-based cohort study of the incidence-trends and prognosis. Ann Rheum Dis 2013;72:1989-1994.
PubMed
P.392 掲載の参考文献
1) Sunderkotter CH, et al.:Nomenclature of Cutaneous Vasculitis:Dermatologic Addendum to the 2012 Revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheumatol 2018;70:171-184.
 
2) Watts RA, et al.:Epidemiology of vasculitis in Europe. Ann Rheum Dis 2001;60:1156-1157.
PubMed
3) Kawazoe M, et al.:Clinical characteristics of patients with polyarteritis nodosa based on a nationwide database in Japan. Mod Rheumatol 2022;32:598-605.
PubMed
4) Luqmani R, et al.:Polyarteritis Nodosa and Related Disorders. In:Firestein GS, et al., eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2021:1634-1648.
 
5) Watts R, et al.:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-227.
PubMed
6) 日本循環器学会, 他:血管炎症候群の診療ガイドライン(2017年改訂版). 日本循環器学会, 2017.
 
7) Pagnoux C, et al.:Clinical features and outcomes in 348 patients with polyarteritis nodosa:a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010;62:616-626.
 
8) Arroyo RA:Medium-vessel vasculitides:polyarteritis nodosa, thromboangiitis obliterans, and primary angiitis of the central nervous system. In:Sterling GW, et al., eds.:Rheumatology Secrets. 4th ed, Elsevier, 2019:236-244.
 
9) Lightfoot RW Jr, et al.:The American College of Rheumatology 1990 criteria for the classification of polyarteritis nodosa. Arthritis Rheum 1990;33:1088-1093.
PubMed
10) Schnappauf O, et al.:Sequence-Based Screening of Patients With Idiopathic Polyarteritis Nodosa, Granulomatosis With Polyangiitis, and Microscopic Polyangiitis for Deleterious Genetic Variants in ADA2. Arthritis Rheumatol 2021;73:512-519.
PubMed
11) 針谷正祥 編:抗リン脂質抗体症候群・好酸球性多発血管炎性肉芽腫症・結節性多発動脈炎・リウマトイド血管炎の治療の手引き2020. 診断と治療社, 2021.
 
12) Guillevin L, et al.:The Five-Factor Score revisited:assessment of prognoses of systemic necrotizing vasculitides based on the French Vasculitis Study Group(FVSG) cohort. Medicine(Baltimore) 2011;90:19-27.
 
P.402 掲載の参考文献
1) Fujimoto S, et al.:Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U. K. Rheumatology(Oxford) 2011;50:1916-1920.
 
2) Tan JA, et al.:Mortality in ANCA-associated vasculitis:a meta-analysis of observational studies. Ann Rheum Dis 2017;76:1566-1574.
PubMed
3) Stone JH:The Antineutrophil Cytoplasmic Antibody-Associated Vasculitides:Wegener's Granulomatosis, Microscopic Polyangiitis, and the Churg-Strauss Syndrome. In:Klippel JH, et al., eds.:Primer on the Rheumatic Diseases, 13th, ed. Springer, 2008:416-426.
 
4) Hunter RW, et al.:ANCA associated vasculitis. BMJ 2020;369:m1070.
PubMed
5) Finkielman JD, et al.:ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007;120:643.e9-643.e14.
 
6) Sada KE, et al.:Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 2014;16:R101.
 
7) Bosch X, et al.:Antineutrophil cytoplasmic antibodies. Lancet 2006;368:404-418.
PubMed
8) Leavitt RY, et al.:The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis. Arthritis Rheum 1990;33:1101-1107.
PubMed
9) Masi AT, et al.:The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-1100.
PubMed
10) Robson JC, et al.:2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Granulomatosis With Polyangiitis. Arthritis Rheumatol 2022;74:393-399.
PubMed
11) Suppiah R, et al.:2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Microscopic Polyangiitis. Arthritis Rheumatol 2022;74:400-406.
PubMed
12) Grayson PC, et al.:2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis With Polyangiitis. Arthritis Rheumatol 2022;74:386-392.
PubMed
13) Jennette JC, et al.:2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.
 
14) Watts R, et al.:Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-227.
PubMed
15) 日本循環器学会, 他;血管炎症候群の診療ガイドライン(2017年改訂版). 日本循環器学会, 2017:57. https://www.j-circ.or.jp/cms/wp-content/uploads/2020/02/JCS2017_isobe_h.pdf(2022年3月閲覧)
 
Casal Moura M, et al.:Efficacy of Rituximab and Plasma Exchange in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Severe Kidney Disease. J Am Soc Nephrol 2020;31:2688-2704.
PubMed
Wallace ZS, et al.:Management of ANCA associated vasculitis. BMJ 2020;368:m421.
PubMed
Moiseev S, et al.:2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev 2020;19:102618.
 
Hunter RW, et al.:ANCA associated vasculitis. BMJ 2020;369:m1070.
PubMed
P.407 掲載の参考文献
1) Walsh M, et al.:PEXIVAS Investigators. Plasma Exchange and Glucocorticoids in Severe ANCA-Associated Vasculitis. N Engl J Med 2020;382:622-631.
PubMed
P.420 掲載の参考文献
1) Fujimoto S, et al.:Comparison of the epidemiology of anti-neutrophil cytoplasmic antibody-associated vasculitis between Japan and the U. K. Rheumatology (Oxford) 2011;50:1916-1920.
 
2) Falk RJ, et al.:Clinical course of anti-neutrophil cytoplasmic autoantibody-associated glomerulonephritis and systemic vasculitis. The Glomerular Disease Collaborative Network. Ann Intern Med 1990;113:656-663.
PubMed
3) Jayne D:The diagnosis of vasculitis. Best Pract Res Clin Rheumatol 2009;23:445-453.
PubMed
4) Hoffman GS, et al.:Wegener granulomatosis:an analysis of 158 patients. Ann Intern Med 1992;116:488-498.
PubMed
5) Kitching AR, et al.:ANCA-associated vasculitis. Nat Rev Dis Primers 2020;6:71.
PubMed
6) Sada KE, et al.:Classification and characteristics of Japanese patients with antineutrophil cytoplasmic antibody-associated vasculitis in a nationwide, prospective, inception cohort study. Arthritis Res Ther 2014;16:R101.
 
7) Schnabel A, et al.:Efficacy of transbronchial biopsy in pulmonary vaculitides. Eur Respir J 1997;10:2738-2743.
PubMed
8) Falk RJ, et al.:Granulomatosis with polyangiitis and microscopic polyangiitis:Clinical manifestations and diagnosis. UpToDate, 2022. https://www.uptodate.com/contents/granulomatosis-with-polyangiitis-and-microscopic-polyangiitis-clinicalmanifestations-and-diagnosis(2022年11月閲覧)
 
9) Lacou M, et al.:Muscle biopsy in anti-neutrophil cytoplasmic antibody-associated vasculitis:diagnostic yield depends on anti-neutrophil cytoplasmic antibody type, sex and neutrophil count. Rheumatology (Oxford) 2021;60:699-707.
PubMed
10) Choi HK, et al.:Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis:prevalence among patients with high titers of antimyeloperoxidase antibodies. Arthritis Rheum 2000;43:405-413.
PubMed
Wallace ZS, et al.:Management of ANCA associated vasculitis. BMJ 2020;368:m421.
PubMed
Moiseev S, et al.:2020 international consensus on ANCA testing beyond systemic vasculitis. Autoimmun Rev 2020;19:102618.
 
Hunter RW, et al.:ANCA associated vasculitis. BMJ 2020;369:m1070.
PubMed
P.427 掲載の参考文献
1) Khoury P, et al.:Eosinophils in vasculitis:characteristics and roles in pathogenesis. Nat Rev Rheumatol 2014;10:474-483.
PubMed
2) Furuta S, et al.:Update on eosinophilic granulomatosis with polyangiitis. Allergol Int 2019;68:430-436.
PubMed
3) Masi AT, et al.:The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis). Arthritis Rheum 1990;33:1094-1100.
PubMed
4) Groh M, et al.:Eosinophilic granulomatosis with polyangiitis(Churg-Strauss)(EGPA) Consensus Task Force recommendations for evaluation and management. Eur J Intern Med 2015;26:545-553.
PubMed
5) 厚生省特定疾患免疫疾患調査研究班 難治性血管炎分科会:平成10年度研究報告書. 1999.
 
6) Grayson PC, et al.:2022 American College of Rheumatology/European Alliance of Associations for Rheumatology Classification Criteria for Eosinophilic Granulomatosis with Polyangiitis. Ann Rheum Dis 2022;81:309-314.
PubMed
7) Dominguez-Quintana M, et al.:Classification of ANCA-associated vasculitis:differences based on ANCA specificity and clinicopathologic phenotype. Rheumatol Int 2021;41:1717-1728.
PubMed
秋田大学大学院医学系研究科医学専攻病態制御医学系 総合診療・検査診断学講座:アレルギー好酸球性炎症の研究. http://www.med.akita-u.ac.jp/~gimclm/research.html(2022年3月閲覧)
 
P.444 掲載の参考文献
Ward MM, et al.:2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis. Arthritis Rheumatol 2019;71:1599-1613. https://www.rheumatology.org/Practice-Quality/Clinical-Support/Clinical-Practice-Guidelines/Axial-Spondyloarthritis
 
Ramiro S, et al.:ASAS-EULAR recommendations for the management of axial spondyloarthritis:2022 update. Ann Rheum Dis 2023;82:19-34. https://ard.bmj.com/content/76/6/978
 
日本皮膚科学会乾癬性関節炎診療ガイドライン作成委員会, 他:乾癬性関節炎診療ガイドライン2019. 日皮会誌 2019;129:2675-2733. https://www.dermatol.or.jp/uploads/uploads/files/guideline/PsAgl2019.pdf
 
日本脊椎関節炎学会, 他 編:脊椎関節炎診療の手引き2020. 診断と治療社, 2020.
 
Gossec L, et al.:EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies:2019 update. Ann Rheum Dis 2020;79:700-712. https://ard.bmj.com/content/79/6/700.1
 
Coates LC, et al.:Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA):updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol 2022;18:465-479. https://www.nature.com/articles/s41584-022-00798-0
 
Singh JA, et al.:2018 American College of Rheumatology/National Psoriasis Foundation Guideline for the Treatment of Psoriatic Arthritis. Arthritis Rheumatol. 2019;71:5-32. https://onlinelibrary.wiley.com/doi/10.1002/art.40726
 
P.445 掲載の参考文献
1) 岸本暢將, 他:脊椎関節炎. 日内会誌 2014;103:2431-2439.
 
2) Raychaudhuri SP, et al.:The classification and diagnostic criteria of ankylosing spondylitis. J Autoimmun 2014;48-49:128-133.
 
3) Calin A, et al.:Clinical history as a screening test for ankylosing spondylitis. JAMA 1977;237:2613-2614.
PubMed
4) Rudwaleit M, et al.:Inflammatory back pain in ankylosing spondylitis:a reassessment of the clinical history for application as classification and diagnostic criteria. Arthritis Rheum 2006;54:569-578.
PubMed
5) Sieper J, et al.:New criteria for inflammatory back pain in patients with chronic back pain:a real patient exercise by experts from the Assessment of SpondyloArthritis international Society(ASAS). Ann Rheum Dis 2009;68:784-788.
PubMed
6) Mease PJ, et al.:Performance of 3 Enthesitis Indices in Patients with Peripheral Spondyloarthritis During Treatment with Adalimumab. J Rheumatol 2017;44:599-608.
PubMed
7) Zeboulon N, et al.:Prevalence and characteristics of uveitis in the spondyloarthropathies:a systematic literature review. Ann Rheum Dis. 2008;67:955-959.
PubMed
8) 日本脊椎関節炎学会, 他 編:脊椎関節炎診療の手引き2020. 診断と治療社, 2020.
 
9) Brockbank JE, et al.:Dactylitis in psoriatic arthritis:a marker for disease severity? Ann Rheum Dis 2005;64:188-190.
PubMed
10) Wilson FC, et al.:Incidence and clinical predictors of psoriatic arthritis in patients with psoriasis:a population-based study. Arthritis Rheum 2009;61:233-239.
PubMed
11) Gottlieb AB, et al.:Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. J Dermatolog Treat 2006;17:279-287.
PubMed
12) Ohara Y, et al.:Prevalence and Clinical Characteristics of Psoriatic Arthritis in Japan, J Rheumatol 2015;42:1439-1442.
PubMed
13) Stolwijk C, et al.:Epidemiology of spondyloarthritis. Rheum Dis Clin North Am 2012;38:441-476.
PubMed
14) Khan MA:HLA-B27 and its subtypes in world populations. Curr Opin Rheumatol 1995;7:263-269.
PubMed
15) Khan MA:HLA-B27 and its pathogenic role. J Clin Rheumatol 2008;14:50-52.
 
16) Khan MA:HLA and Spondyloarthropathies. In:Mehra N, ed.:The HLA Complex in Biology and Medicine. Jaypee Brothers Medical Publishers, 2010:259-275.
 
17) Reveille JD, et al.:The prevalence of HLA-B27 in the US:data from the US National Health and Nutrition Examination Survey, 2009. Arthritis Rheum 2012;64:1407-1411.
PubMed
18) Dean LE, et al.:Global prevalence of ankylosing spondylitis. Rheumatology(Oxford) 2014;53:650-657.
PubMed
19) Bittar M, et al.:Worldwide Differences in Clinical Phenotype of Axial Spondyloarthritis. Curr Rheumatol Rep 2021;23:76.
PubMed
20) Kishimoto M, et al.:Clinical Characteristics of Patients with Spondyloarthritis in Japan in Comparison with Other Regions of the World, J Rheumatol 2019;46:896-903.
 
21) van der Linden S, et al.:Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-368.
PubMed
22) Bennett PH, et al.:Population studies of the rheumatic diseases;proceedings of the third international symposium, New York, June 5th-10th, 1966. International Congress Series 1966;148:456-457.
 
23) Rudwaleit M, et al.:The challenge of diagnosis and classification in early ankylosing spondylitis:do we need new criteria? Arthritis Rheum 2005;52:1000-1008.
PubMed
24) Lambert RG, et al.:Defining active sacroiliitis on MRI for classification of axial spondyloarthritis:update by the ASAS MRI working group. Ann Rheum Dis 2016;75:1958-1963.
 
25) Rudwaleit M, et al.:The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis(part II):validation and final selection. Ann Rheum Dis 2009;68:777-783.
PubMed
26) Rudwaleit M, et al.:The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011;70:25-31.
PubMed
27) Taylor W, et al.:Classification criteria for psoriatic arthritis:development of new criteria from a large international study. Arthritis Rheum 2006;54:2665-2673.
 
28) Yamamoto T, et al.:Epidemiological analysis of psoriatic arthritis patients in Japan. J Dermatol 2016;43:1193-1196.
PubMed
29) Zink A, et al.:The national database of the German Collaborative Arthritis Centres:I. Structure, aims, and patients. Ann Rheum Dis 2001;60:199-206.
PubMed
P.455 掲載の参考文献
1) Salvarani C, et al.:Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 2002;347:261-271.
PubMed
2) Hellmann DB:Giant Cell Arteritis, Polymyalgia Rheumatica, and Takayasu's Arteritis. In:Firestein GS, et al., eds.:Firestein & Kelly's Textbook of Rheumatology, 11th ed. Elsevier, 2021:1595-1616.
 
3) Salvarani C, et al.:Clinical features of polymyalgia rheumatica and giant cell arteritis. Nat Rev Rheumatol 2012;8:509-512.
PubMed
4) Dejaco C, et al.:2015 recommendations for the management of polymyalgia rheumatica:a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheumatol 2015;67:2569-2580.
PubMed
5) Gran JT, et al.:The incidence and clinical characteristics of peripheral arthritis in polymyalgia rheumatica and temporal arteritis:a prospective study of 231 cases. Rheumatology(Oxford) 2000;39:283-287.
PubMed
6) Dasgupta B, et al.:2012 Provisional classification criteria for polymyalgia rheumatica:a European League Against Rheumatism/American College of Rheumatology collaborative initiative. Arthritis Rheum 2012;64:943-954.
PubMed
7) Salvarani C, et al.:Acute-phase reactants and the risk of relapse/recurrence in polymyalgia rheumatica:a prospective followup study. Arthritis Rheum 2005;53:33-38.
PubMed
8) Ochi J, et al.:MRI findings of the shoulder and hip joint in patients with polymyalgia rheumatica. Mod Rheumatol 2015;25:761-767.
PubMed
9) Dasgupta B, et al.:BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010;49:186-190.
PubMed
10) Muller S, et al.:Is cancer associated with polymyalgia rheumatica? A cohort study in the General Practice Research Database. Ann Rheum Dis 2014;73:1769-1773.
PubMed
11) 竹田剛:高齢関節リウマチ患者の治療戦略. 日臨免疫会誌 2016;39:497-504.
 
12) Pease CT, et al.:Polymyalgia rheumatica can be distinguished from late onset rheumatoid arthritis at baseline:results of a 5-yr prospective study. Rheumatology(Oxford) 2009;48:123-127.
PubMed
13) Manger B, et al.:Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol 2014;10:662-670.
PubMed
P.466 掲載の参考文献
1) Mattoo H, et al.:Clonal expansion of CD4 (+) cytotoxic T lymphocytes in patients with IgG4-related disease. J Allergy Clin Immunol 2016;138:825-838.
PubMed
2) Zhang W, et al.:Management of IgG4-related disease. Lancet Rheumatol 2019;1:e55-e65.
 
3) Inoue D, et al.:IgG4-related disease:dataset of 235 consecutive patients. Medicine (Baltimore) 2015;94:e680.
PubMed
4) Della-Torre E, et al.:"How I manage" IgG4-Related Disease. J Clin Immunol 2016;36:754-763.
 
5) 梅原久範, 他:2020年改訂IgG4関連疾患包括診断基準. 日内会誌 2021;110:962-969.
 
6) Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2011;127:18-27;quiz 28-29.
 
7) Takuma K, et al.:Autoimmune pancreatitis and IgG4-related sclerosing cholangitis. Curr Opin Rheumatol 2011;23:80-87.
PubMed
8) Deshpande V, et al.:Consensus statement on the pathology of IgG4-related disease. Mod Pathol 2012;25:1181-1192.
PubMed
9) 岡崎和一, 他:臨床医必読 最新IgG4関連疾患 改訂第2版. 診断と治療社, 2019:vi.
 
10) Sakamoto M, et al.:The diagnostic utility of submandibular gland sonography and labial salivary gland biopsy in IgG4-related dacryoadenitis and sialadenitis:Its potential application to the diagnostic criteria. Mod Rheumatol 2020;30:379-384.
 
11) Komori T, et al.:Ultrasonography of IgG4-related dacryoadenitis and sialadenitis:Imaging features and clinical usefulness. Mod Rheumatol 2021:roab063.
 
12) Wallace ZS, et al.:The 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-related disease. Ann Rheum Dis 2019;79:77-87.
PubMed
13) Khosroshahi A, et al.:International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67:1688-1699.
PubMed
14) Wang L, et al.:Sex disparities in clinical characteristics and prognosis of immunoglobulin G4-related disease:a prospective study of 403 patients. Rheumatology(Oxford) 2018;58:820-830.
 
15) Sasaki T, et al.:Risk factors of relapse following glucocorticoid tapering in IgG4-related disease. Clin Exp Rheumatol 2018;36(suppl 112):186-189.
 
16) Wallace ZS, et al.:Predictors of disease relapse in IgG4-related disease following rituximab. Rheumatology (Oxford) 2016;55:1000-1008.
PubMed
17) Culver EL, et al.:Increases in IgE, eosinophils, and mast cells can be used in diagnosis and to predict relapse of IgG4-related disease. Clin Gastroenterol Hepatol 2017;15:1444-1452.
PubMed
18) Kubota K, et al.:Low-dose maintenance steroid treatment could reduce the relapse rate in patients with type 1 autoimmune pancreatitis:a long-term Japanese multicenter analysis of 510 patients. J Gastroenterol 2017;52:955-964.
PubMed
P.472 掲載の参考文献
1) Dalbeth N, et al.:Relationship between serum urate concentration and clinically evident incident gout:an individual participant data analysis. Ann Rheum Dis 2018;77:1048-1052.
PubMed
2) Dalbeth N, et al.:Gout. Lancet 2016;388:2039-2052.
PubMed
3) Choi HK, et al.:Nocturnal risk of gout attacks. Arthritis Rheumatol 2015;67:555-562.
PubMed
4) Richette P, et al.:2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis 2017;76:29-42.
PubMed
5) FitzGerald JD, et al.:2020 American College of Rheumatology Guideline for the Management of Gout. Arthritis Rheumatol 2020;72:879-895.
PubMed
P.481 掲載の参考文献
1) Szekanecz Z, et al.:Autoinflammation and autoimmunity across rheumatic and musculoskeletal diseases. Nat Rev Rheumatol 2021;17:585-595.
PubMed
2) Asanuma YF, et al.:Nationwide epidemiological survey of 169 patients with adult Still's disease in Japan. Mod Rheumatol 2015;25:393-400.
PubMed
3) Efthimiou P, et al.:Adult-onset Still's disease in focus:Clinical manifestations, diagnosis, treatment, and unmet needs in the era of targeted therapies. Semin Arthritis Rheum 2021;51:858-874.
PubMed
4) Kalyoncu U, et al.:Response rate of initial conventional treatments, disease course, and related factors of patients with adult-onset Still's disease:data from a large multicenter cohort. J Autoimmun 2016;69:59-63.
PubMed
5) Chen PD, et al.:Retrospective study of 61 patients with adultonset Still's disease admitted with fever of unknown origin in China. Clin Rheumatol 2012;31:175-181.
 
6) Cozzi A, et al.:Cutaneous manifestations of adult-onset Still's disease:a case report and review of literature. Clin Rheumatol 2016;35:1377-1382.
PubMed
7) Franchini S, et al.:Adult-onset Still's disease:clinical presentation in a large cohort of Italian patients. Clin Exp Rheumatol 2010;28:41-48.
 
8) Liu Z, et al.:Clinical features and prognosis of adult-onset Still's disease:75 cases from China. Int J Clin Exp Med 2015;8:16634-16639.
PubMed
9) 厚生労働科学研究費補助金難治性疾患等政策研究事業 自己免疫疾患に関する調査研究班 編:成人スチル病診療ガイドライン 2017年版. 診断と治療社, 2017. https://minds.jcqhc.or.jp/docs/gl_pdf/G0001020/4/Adult_Stills_Disease.pdf(2022年3月閲覧)
 
10) Yang XP, et al.:Predictive factors and prognosis of macrophage activation syndrome associated with adult-onset Still's disease. Clin Exp Rheumatol 2019;37:83-88.
PubMed
11) Ruscitti P, et al.:Macrophage activation syndrome in patients affected by adult-onset Still disease:analysis of survival rates and predictive factors in the Gruppo Italiano di Ricerca in reumatologia clinica e sperimentale cohort. J Rheumatol 2018;45:864-872.
PubMed
12) Mitrovic S, et al.:Complications of adult-onset Still's disease and their management. Exp Rev Clin Immunol 2018;14:351-365.
 
13) Yamaguchi M, et al.:Preliminary criteria for classification of adult Still's disease. J Rheumatol 1992;19:424-430.
 
14) Lian F, et al.:Clinical features and hyperferritinemia diagnostic cutoff points for AOSD based on ROC curve:a Chinese experience. Rheumatol Int 2012;32:189-192.
PubMed
15) Kawaguchi Y, et al.:Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still's disease. Arthritis Rheum 2001;44:550-560.
 
16) Gerfaud-Valentin M, et al.:Adult-onset Still's disease. Autoimmun Rev 2014;13:708-722.
PubMed
17) 三村俊英:成人Still病の診断と治療. 日内会誌 2018;107:1892-1898.
 
18) Govoni M, et al.:How I treat patients with adult onset Still's disease in clinical practice. Autoimmun Rev 2017;16:1016-1023.
 
19) Feist E, et al.:Mechanisms, biomarkers and targets for adult-onset Still's disease. Nat Rev Rheumatol 2018;14:603-618.
PubMed
20) Kaneko Y, et al.:Tocilizumab in patients with adult-onset still's disease refractory to glucocorticoid treatment:a randomised, double-blind, placebo-controlled phase III trial. Ann Rheum Dis 2018;77:1720-1729.
PubMed
21) Kedor C, et al.:Canakinumab for treatment of adult-onset Still's disease to achieve reduction of arthritic manifestation (CONSIDER):phase II, randomised, double-blind, placebo-controlled, multicentre, investigator-initiated trial. Ann Rheum Dis 2020;79:1090-1097.
PubMed
22) Hu Q, et al.:Tofacitinib in refractory adult-onset still's disease:14 cases from a single centre in China. Ann Rheum Dis 2020;79:842-844.
 
P.489 掲載の参考文献
1) Christine S, et al.:Behcet's Disease. In:Firestein G, et al., eds.:Firestein & Kelley's Textbook of Rheumatology, 11th ed. Elsevier, 2021:1666-1675.
 
2) Smith EL, et al.:Clinical manifestations and diagnosis of Behcet syndrome. UpToDate, 2021. https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-behcet-syndrome(2022年3月閲覧)
 
3) West SG:Behcet's Disease and Cogan's Syndrome. In:Kolfenbach J, ed.:Rheumatology Secrets, 4th ed. Elsevier, 2020:271-276.
 
4) 日本ベーチェット病学会 監, 厚生労働科学研究費補助金(難治性疾患政策研究事業)ベーチェット病に関する調査研究班, 他 編:ベーチェット病診療ガイドライン2020. 診断と治療社, 2020.
 
5) 難病情報センター:ベーチェット病. https://www.nanbyou.or.jp/entry/330(2022年3月閲覧)
 
6) Lodi D:Oral lesions. UpToDate, 2021. https://www.uptodate.com/contents/oral-lesions(2022年3月閲覧)
 
7) Keogan MT:Clinical Immunology Review Series:an approach to the patient with recurrent orogenital ulceration, including Behcet's syndrome. Clin Exp Immunol 2009;156:1-11.
 
8) International Study Group for Behcet's Disease:Criteria for diagnosis of Behcet's disease. Lancet 1990;335:1078-1080.
 
9) International Team for the Revision of the International Criteria for Behcet's Disease (ITR-ICBD):The International Criteria for Behcet's Disease (ICBD):a collaborative study of 27 countries on the sensitivity and specificity of the new criteria. J Eur Acad Dermatol Venereol 2014;28:338-347.
 
P.500 掲載の参考文献
1) Ruiz-Irastorza G, et al.:Antiphospholipid syndrome. Lancet 2010;376:1498-1509.
PubMed
2) 阿部靖矢, 他:抗リン脂質抗体症候群. 日血栓止血会誌 2018;29:294-306.
 
3) 御舘靖雄, 他:ループスアンチコアグラントの検出について-冠攣縮性狭心症から心筋梗塞をきたした1例を通じて. 日血栓止血会誌 2001;12:493-499.
 
4) Katrien MJ, et al.:Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 2020;11:2828-2839.
 
5) Miyakis S, et al.:International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome(APS). J Thromb Haemost 2006;4:295-306.
 
6) Tektonidou MG, et al.:EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019;78:1296-1304.
PubMed
7) Giannakopoulos B, et al.:The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013;368:1033-1044.
PubMed
8) Cohen H, et al.:Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS):a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol 2016;3:e426-e436.
 
P.509 掲載の参考文献
1) Jaksch-Wartenhorst R:Polychondropathia. Arch Inn Med 1923;6:93-100.
 
2) Pearson CM, et al.:Relapsing polychondritis. N Engl J Med 1960;263:51-58.
PubMed
3) McAdam LP, et al.:Relapsing polychondritis:prospective study of 23 patients and a review of the literature. Medicine (Baltimore) 1976;55:193-215.
 
4) Damiani JM, et al.:Relapsing polychondritis--report of ten cases. Laryngoscope 1979;89:929-946.
PubMed
5) Michet CJ, et al.:Relapsing polychondritis:Survival and Predictive Role of Early Disease Manifestations. Ann Intern Med 1986;104:74-78.
PubMed
6) Kingdon J, et al.:Relapsing polychondritis:a clinical review for rheumatologists. Rheumatology(Oxford) 2018;57:1525-1532.
PubMed
7) Gergely P, et al.:Relapsing polychondritis. Best Pract Res Clin Rheumatol 2004;18:723-738.
PubMed
8) 再発性多発軟骨炎の診断と治療体系の確立 平成21年度 総括・分担研究報告書. 厚生労働科学研究費補助金 難治性疾患克服研究事業(研究代表者 鈴木登). 2010. http://www.marianna-u.ac.jp/rp/doc/21/21-1.pdf(2022年3月閲覧)
 
9) Borgia F, et al.:Relapsing Polychondritis:An Updated Review. Biomedicines 2018;6:84.
PubMed
10) Bielajew BJ, et al.:Collagen:quantification, biomechanics, and role of minor subtypes in cartilage. Nat Rev Mater 2020;5:730-747.
PubMed
11) Beck DB, et al.:Somatic Mutations in UBA1 and Severe Adult-Onset Autoinflammatory Disease. N Engl J Med 2020;383:2628-2638.
PubMed
12) Lee KS, et al.:Relapsing polychondritis:prevalence of expiratory CT airway abnormalities. Radiology 2006;240:565-573.
PubMed
13) Arnaud L, et al.:The Relapsing Polychondritis Disease Activity Index:development of a disease activity score for relapsing polychondritis. Autoimmun Rev 2012;12:204-209.
PubMed
P.519 掲載の参考文献
1) Brouet JC, et al.:Biologic and clinical significance of cryoglobulins. A report of 86 cases. Am J Med 1974;57:775-788.
PubMed
2) Ramos-Casals M, et al.:The cryoglobulinaemias. Lancet 2012;379:348-360.
PubMed
3) Cacoub P, et al.:Cryoglobulinemia Vasculitis. Am J Med 2015;128:950-955.
PubMed
4) 住田孝之, 編:EXPERT 膠原病・リウマチ改訂第4版. 診断と治療社, 2019:v.
 
5) Dammacco F, et al.:Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. N Engl J Med 2013;369:1035-1045.
PubMed
6) Roccatello D, et al.:Cryoglobulinaemia. Nat Rev Dis Primers 2018;4:11.
PubMed
7) Vassilopoulos D:Cryoglobulinemia. In:Stone JH, et al., eds.:A Clinician's Pearls and Myths in Rheumatology. Springer, 2009:269-273.
 
8) Muchtar E, et al.:How I treat cryoglobulinemia. Blood 2017;129:289-298.
 
9) Fervenza FC, et al.:Mixed cryoglobulinemia syndrome:Treatment and prognosis. UpToDate, 2022.
 
10) Retamozo S, et al.:Life-Threatening Cryoglobulinemic Patients With Hepatitis C:Clinical Description and Outcome of 279 Patients. Medicine(Baltimore) 2013;92:273-284.
PubMed
11) Terrier B, et al.:Prognostic factors of survival in patients with non-infectious mixed cryoglobulinaemia vasculitis:data from 242 cases included in the CryoVas survey. Ann Rheum Dis 2013;72:374-380.
PubMed
P.525 掲載の参考文献
1) Ohl CA:Infectious Arthritis of Native Joints. In:Bennett JE, et al., eds.:Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases, 9th ed. Elsevier, 2020:1400-1417.
 
2) Mader JT, et al.:The host and the skeletal infection:classification and pathogenesis of acute bacterial bone and joint sepsis. Baillieres Best Pract Res Clin Rheumatol 1999;13:1-20.
PubMed
3) McBride S, et al.:Epidemiology, Management, and Outcomes of Large and Small Native Joint Septic Arthritis in Adults. Clin Infect Dis 2020;70:271-279.
PubMed
4) Ross JJ, et al.:Pneumococcal septic arthritis:review of 190 cases. Clin Infect Dis 2003;36:319-327.
PubMed
5) Mathew AJ, et al.:Infections and arthritis. Best Pract Res Clin Rheumatol 2014;28:935-959.
PubMed
6) Christopher R, et al.:Evidence-based diagnostics:adult septic arthritis. Acad Emerg Med 2011;18:781-796.
 
7) Schmerling RH, et al.:Synovial fluid tests:what should be ordered? JAMA 1990;264:1009-1014.
 
8) Kortekangas P, et al.:Synovial fluid leukocytosis in bacterial arthritis vs reactive arthritis and rheumatoid arthritis in the adult knee. Scan J Rheumatol 1992;21:283-288
 
9) Gratacos J, et al.:D-lactic acid in synovial fluid. A rapid diagnostic test for bacterial synovitis. J Rheumatol 1995;22:1504-1508.
PubMed
10) Soderquist B, et al.:Bacterial or crystal-associated arthritis? Discriminating ability of serum inflammatory markers. Scan J Infect Dis 1998;30:591-596.
 
11) Brook I, et al.:Synovial fluid lactic acid. A diagnostic aid in septic arthritis. Arthritis Rheum 1978;21:774-779.
PubMed
12) Mossman SS, et al.:Synovial fluid lactic acid in septic arthritis. N Z Med J 1981;93:115-117.
PubMed
13) Riordan T, et al.:Synovial fluid lactic acid measurement in the diagnosis and management of septic arthritis. J Clin Pathol 1982;35:390-394.
PubMed
P.531 掲載の参考文献
1) Marks M, et al.:Viral arthritis. Clin Med(Lond) 2016;16:129-134.
PubMed
2) Vassilopouros D, et al.:Rheumatologic aspects of viral infections. In:Hochberg MC, et al., eds.:Rheumatology, 6th ed. Mosby/Elsevier, 2015:912-917.
 
3) Varache S, et al.:Is routine viral screening useful in patients with recent-onset polyarthritis of a duration of at least 6 weeks? Results from a nationwide longitudinal prospective cohort study. Arthritis Care Res(Hoboken)2011;63:1565-1570.
PubMed
4) Kaul R:Hepatitis. In:Wild D, ed.:The Immunoassay Handbook:Theory and Applications of Ligand Binding, ELISA and Related Techniques, 4th ed. Elsevier, 2013:901-911.
 
5) Centre for Disease Analysis:Web Annex B. WHO estimates of the prevalence and incidence of hepatitis C virus infection by WHO region, 2015. In:Global hepatitis report 2017. World Health Organization, 2018. https://www.who.int/publications/i/item/9789241565455(2022年10月閲覧)
 
6) Afzal W, et al.:Viral Arthritides. In:West SG, et al., eds.:Rheumatology Secrets, 4th ed. Elsevier, 2019:340-345.
 
P.542 掲載の参考文献
1) Seo P, et al.:The antineutrophil cytoplasmic antibody-associated vasculitides. Am J Med 2004;117:39-50.
PubMed
2) Hoffman GS, et al.:Wegener granulomatosis:an analysis of 158 patients. Ann Intern Med 1992;116:488-498.
PubMed
3) Jennette JC, et al.:ANCA Glomerulonephritis and Vasculitis. Clin J Am Soc Nephrol 2017;12:1680-1691
 
4) Jennette JC, et al.:The pathology of vasculitis involving the kidney. Am J Kidney Dis 1994;24:130-141.
PubMed
5) Segelmark M, et al.:Anti-glomerular basement membrane disease:an update on subgroups, pathogenesis and therapies. Nephrol Dial Transplant 2019;34:1826-1832.
PubMed
6) Butler EA, et al.:Generation of a Core Set of Items to Develop Classification Criteria for Scleroderma Renal Crisis Using Consensus Methodology. Arthritis Rheumatol 2019;71:964-971.
PubMed
7) Woodworth TG, et al.:Scleroderma renal crisis and renal involvement in systemic sclerosis. Nat Rev Nephrol 2016;12:678-691.
PubMed
8) Shanmugam VK, et al.:Renal manifestations in scleroderma:evidence for subclinical renal disease as a marker of vasculopathy. Int J Rheumatol 2010;538589.
PubMed
9) Batal I, et al.:Scleroderma renal crisis:a pathology perspective. Int J Rheumatol 2010;2010:543704.
PubMed
10) Varga J, et al.:Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis. UpToDate, 2022. https://www.uptodate.com/contents/kidney-disease-in-systemic-sclerosis-scleroderma-including-scleroderma-renal-crisis(2022年10月閲覧)
 
11) Steen VD, et al.:Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-603.
PubMed
12) Soleimani M, et al.:Pathophysiology of Renal Tubular Acidosis:Core Curriculum 2016. Am J Kidney Dis 2016;68:488-498.
PubMed
13) Both T, et al.:Prevalence of distal renal tubular acidosis in primary Sjogren's syndrome. Rheumatology (Oxford) 2015;54:933-939.
PubMed
14) Lindner G, et al.:Hypercalcemia in the ED;Prevalence, etiology, and outcome. Am J Emerg Med 2013;31:657-660.
PubMed
15) 龍華章裕:高Ca血症の診かた考え方. 藤田芳郎, 他 編:研修医のための輸液・水電解質・酸塩基平衡. 中外医学社, 2015:226.
 

3 治療編

P.550 掲載の参考文献
1) von der Goes MC, et al.:Glucocorticoid therapy. In:Firestein GS, et al., eds.:Firestein & Kelly's Textbook of Rheumatology, 11th ed. Elsevier, 2020:985-1006.
 
2) Porta S, et al.:Glucocorticoids in Systemic Lupus Erythematosus. Ten Questions and Some Issues. J Clin Med 2020;9:2709.
PubMed
3) Buttgereit F, et al.:Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens:current questions and tentative answers in rheumatology. Ann Rheum Dis 2002;61:718-722.
PubMed
4) West SG:Glucocorticoids-Systemic and Injectable. In:Kolfenbach J, ed.:Rheumatology Secrets, 4th ed. Elsevier, 2019:655-661.
 
P.555 掲載の参考文献
1) 日本消化器病学会 編:消化性潰瘍診療ガイドライン2020(改訂第3版). 南江堂, 2020.
 
2) Nissen SE, et al.:Cardiovascular safety of celecoxib, naproxen, or ibuprofen for arthritis. N Engl J Med 2016;375:2519-2529.
 
3) Naughton CA:Drug-induced nephrotoxicity. Am Fam Physician 2008;78:743-750.
PubMed
4) Awdishu L, et al.:The 6R's of drug induced nephrotoxicity. BMC Nephrol 2017;18:124.
PubMed
Schjerning Olsen AM, et al.:Association of NSAID use with risk of bleeding and cardiovascular events in patients receiving antithrombotic therapy after myocardial infarction. JAMA 2015;313:805-814.
PubMed
Batlouni M:Anti-inflamatorios nao esteroides:Efeitos cardiovasculares, cerebro-vasculares e renais [Nonsteroidal antiinflammatory drugs:cardiovascular, cerebrovascular and renal effects]. Arq Bras Cardiol 2010;94:556-563. Portuguese.
PubMed
P.564 掲載の参考文献
1) 岡田正人:膠原病の病態と治療のキーポイント. medicina 2009;46:1448-1451.
 
2) Ruiz-Irastorza G, et al.:Treating systemic lupus erythematosus in the 21st century:new drugs and new perspectives on old drugs. Rheumatology (Oxford) 2020;59:v69-v81.
PubMed
3) Kondo T, et al.:Era of steroid sparing in the management of immune-mediated inflammatory diseases. Immunol Med 2018;41:6-11.
PubMed
4) Van Laar JM:Immunosuppressive Drugs. In:Firestein GS, et al., eds.:Kelley and Firestein's Textbook of Rheumatology, 10th ed. Elsevier, 2017:983-998.
 
5) 日本リウマチ学会MTX診療ガイドライン策定小委員会 編:関節リウマチ治療におけるメトトレキサート(MTX)診療ガイドライン 2016年改訂版. 羊土社, 2016.
 
6) Austin HA 3rd, et al.:Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-619.
PubMed
7) Houssiau FA, et al.:Immunosuppressive therapy in lupus nephritis:the Euro-Lupus Nephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 2002;46:2121-2131.
 
8) 角田洋一:Nudix hydrolase 15(NUDT15)遺伝子多型検査. Mod Media 2019;65:156-161.
 
9) Nomura A, et al.:Efficacy and safety of multitarget therapy with mizoribine and tacrolimus for systemic lupus erythematosus with or without active nephritis. Lupus 2012;21:1444-1449.
PubMed
P.566 掲載の参考文献
1) Gladman DD, et al.:Accrual of organ damage over time in patients with systemic lupus erythematosus. J Rheumatol 2003;30:1955-1959.
PubMed
2) Thamer M, et al.:Prednisone, lupus activity, and permanent organ damage. J Rheumatol 2009;36:560-564.
PubMed
3) van Vollenhoven RF, et al.:Treat-to-target in systemic lupus erythematosus:recommendations from an international task force. Ann Rheum Dis 2014;73:958-967.
PubMed
4) Franklyn K, et al.:Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016;75:1615-1621.
PubMed
P.571 掲載の参考文献
1) 厚生労働省科学研究費補助金 平成27年度日本医療開発機構腎疾患実用化研究事業「慢性腎臓病の進行を促進する薬剤等による腎障害の早期診断法と治療法の開発」薬剤性腎障害の診療ガイドライン作成委員会:薬剤性腎障害診療ガイドライン2016. 日腎会誌 2016;58:477-555.
 
2) Gonzalez E, et al.:Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008;73:940-946.
PubMed
3) Obayashi M, et al.:Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis. Clin Exp Nephrol 2003;7:275-278.
PubMed
Chronopoulos A, et al.:Hospital-acquired acute kidney injury in the elderly. Nat Rev Nephrol 2010;6:141-149.
PubMed
日本腎臓学会, 他 編:腎障害患者におけるヨード造影剤使用に関するガイドライン2018. 東京医学社. 2018.
 
日本化学療法学会/日本TDM学会抗菌薬TDMガイドライン作成委員会 編:抗菌薬TDMガイドライン2016. 日本化学療法学会/日本TDM学会, 2016. http://www.chemotherapy.or.jp/guideline/tdm_es.pdf(2022年4月閲覧)
 
Muriithi AK, et al.:Clinical characteristics, causes and outcomes of acute interstitial nephritis in the elderly. Kidney Int 2014;87:458-464.
PubMed
Gonzalez E, et al.:Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008;73:940-946.
PubMed
P.574 掲載の参考文献
1) Praga M, et al.:Changes in the aetiology, clinical presentation and management of acute interstitial nephritis, an increasingly common cause of acute kidney injury. Nephrol Dial Transplant 2015;30:1472-1479.
PubMed
2) Gonzalez E, et al.:Early steroid treatment improves the recovery of renal function in patients with drug-induced acute interstitial nephritis. Kidney Int 2008;73:940-946.
PubMed
3) Bhaumik SK, et al.:Evaluation of clinical and histological prognostic markers in drug-induced acute interstitial nephritis. Ren Fail 1996;18:97-104.
PubMed
4) Raza MN, et al.:Acute tubulointerstitial nephritis, treatment with steroid and impact on renal outcomes. Nephrology (Carlton) 2012;17:748-753.
PubMed
P.583 掲載の参考文献
1) Zhang Y, et al.:Assessment of the impact of renal impairment on systemic exposure of new molecular entities:evaluation of recent new drug applications. Clin Pharmacol Ther 2009;85:305-311.
PubMed
2) Matsuo S, et al.:Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis 2009;53:982-992.
PubMed
3) Horio M, et al.:Performance of serum cystatin C versus serum creatinine as a marker of glomerular filtration rate as measured by inulin renal clearance. Clin Exp Nephrol 2011;15:868-876.
PubMed
4) Horio M, et al.:Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese:accuracy and use for population estimates. Am J Kidney Dis 2010;56:32-38.
PubMed
5) Inker LA, et al.:New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race. N Engl J Med 2021;385:1737-1749.
 
P.593 掲載の参考文献
1) Crees Z, et al., eds.:The Washington Manual(R) of Medical Therapeutics, 36th ed. Lippincott Williams & Wilkins, 2019 (Brown AL, et al.:高血圧症. In:Crees Z, et al., eds., 高久史麿, 他 監訳:ワシントンマニュアル, 第14版. メディカル・サイエンス・インターナショナル, 2021:71-91).
 
2) 日本高血圧学会高血圧治療ガイドライン作成委員会 編:高血圧治療ガイドライン2019. 日本高血圧学会, 2019.
 
3) 日本高血圧学会高血圧診療ガイド2020作成委員会 編:高血圧診療ガイド2020. 文光堂, 2020.
 
4) Fujiyoshi A, et al.:Blood pressure categories and long-term risk of cardiovascular disease according to age group in Japanese men and women. Hypertens Res 2012;35:947-953.
PubMed
5) Saint S, et al., eds.:The Saint-Chopra Guide to Inpatient Medicine, 4th ed. Oxford University Press, 2018(McGuire M, et al. 執筆, 鈴木智晴 監訳, 須田和佳子 訳:高血圧症. In:Saint S, et al., eds., 徳田安春 監, 栗原健, 他 監訳:セイントとチョプラの内科診療ガイド第3版. メディカル・サイエンス・インターナショナル, 2020:310-316).
 
6) Mann JF:Overview of hypertension in acute and chronic kidney disease. UpToDate, 2022. https://www.uptodate.com/contents/overview-of-hypertension-in-acute-and-chronic-kidney-disease(2022年5月閲覧)
 
7) Buckalew VM, et al.:Prevalence of hypertension in 1,795 subjects with chronic renal disease:the modification of diet in renal disease study baseline cohort. Modification of Diet in Renal Disease Study Group. Am J Kidney Dis 1996;28:811-821.
 
8) 下澤達雄:降圧治療のエッセンスとポイント. 循環器ジャーナル 2022;70:300-306.
 
9) World Health Organization:Guideline for the pharmacological treatment of hypertension in adults. World Health Organization, 2021.
 
10) Kent DM, et al.:Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol 2007;18:1959-1965.
PubMed
11) Imai E, et al.:Blood pressure drop in summer may cause acute kidney injury with irreversible reduction of glomerular filtration rate. Clin Exp Nephrol 2013;17:1-2.
PubMed
12) Nagaraja V:Management of scleroderma renal crisis. Curr Opin Rheumatol 2019;31:223-230.
PubMed
13) Varga J, et al.:Kidney disease in systemic sclerosis (scleroderma), including scleroderma renal crisis. UpToDate, 2021. https://www.uptodate.com/contents/kidney-disease-in-systemic-sclerosis-scleroderma-including-scleroderma-renal-crisis(2022年5月閲覧)
 
14) Steen VD, et al.:Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-603.
PubMed
P.604 掲載の参考文献
1) 日本腎臓学会 編:CKD診療ガイド2012. 東京医学社, 2012. https://jsn.or.jp/guideline/pdf/CKDguide2012.pdf(2022年6月閲覧)
 
2) 日本腎臓学会 編:エビデンスに基づくCKDガイドライン2018. 東京医学社, 2018. https://cdn.jsn.or.jp/data/CKD2018.pdf(2022年6月閲覧)
 
3) Parmar MS:Chronic renal disease. BMJ 2002;325:85-90.
PubMed
4) 日本腎臓学会 編:生活習慣病からの新規透析導入患者の減少に向けた提言-CKD(慢性腎臓病)の発症予防・早期発見・重症化予防. 東京医学社, 2016. https://cdn.jsn.or.jp/guideline/pdf/2016-jsn-lifestyle-related-disease.pdf(2022年6月閲覧)
 
5) Taal MW:Classification and Management of Chronic Kidney Disease. In:Yu ASL, et al., eds.:Brenner and Rector's The Kidney, 11th ed. Elsevier, 2019:1946-1976.
 
6) 木村健二郎:CKD進展予防のための保健指導教材. 厚生労働科学研究費補助金 難治性疾患等克服研究事業CKD進展予防のための特定健診と特定保健指導のあり方に関する研究. 2013. https://cdn.jsn.or.jp/academicinfo/report/201303.pdf(2022年6月閲覧)
 
7) 日本腎臓学会 編:慢性腎臓病に対する食事療法基準2014年版. 東京医学社, 2014. https://cdn.jsn.or.jp/guideline/pdf/CKD-Dietaryrecommendations2014.pdf(2022年6月閲覧)
 
8) Watanabe D, et al.:Age Modifies the Association of Dietary Protein Intake with All-Cause Mortality in Patients with Chronic Kidney Disease. Nutrients 2018;10:1744.
PubMed
9) American Diabetes Association Professional Practice Committee:9. Pharmacologic Approaches to Glycemic Treatment:Standards of Medical Care in Diabetes-2022. Diabetes Care 2022;45(Suppl 1):S125-S143.
 
10) 日本動脈硬化学会 編:動脈硬化性疾患予防ガイドライン2017年版. 日本動脈硬化学会, 2017.
 
11) 日本動脈硬化学会 編:動脈硬化性疾患予防ガイドライン2022年版. 日本動脈硬化学会, 2022. https://www.j-athero.org/jp/jas_gl2022/(2022年11月閲覧)
 
12) 内田啓子, 他:日本腎臓学会 HIF-PH 阻害薬適正使用に関するrecommendation. 日腎会誌 2020;62:711-716.
 
13) 日本透析医学会:慢性腎臓病に伴う骨・ミネラル代謝異常の診療ガイドライン. 日透析医学会誌 2012;45:301-356.
 
14) Isakova T, et al.:KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis 2017;70:737-751.
PubMed
15) 骨粗鬆症の予防と治療ガイドライン作成委員会 編:骨粗鬆症の予防と治療ガイドライン2015年版. ライフサイエンス出版, 2015. http://www.josteo.com/ja/guideline/doc/15_1.pdf(2022年6月閲覧)
 
16) 稲葉雅章:特集 CKDにおける骨粗鬆症治療薬の使い方. 日本医事新報2022;5121:18-26.
 
17) Khairallah P, et al.:Management of Osteoporosis in CKD. Clin J Am Soc Nephrol 2018;13:962-969.
PubMed
18) KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int 2013;3(Suppl 1):1-150.
 
19) 志水英明:日常診療で役立つNa-Clを用いた酸塩基平衡異常の鑑別と注意点. 日内会誌 2022;111:1-8.
 
20) McDonagh TA, et al.:2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J 2021;42:3599-3726.
PubMed
21) Palmer BF, et al.:Physiology and Pathophysiology of Potassium Homeostasis:Core Curriculum 2019. Am J Kidney Dis 2019;74:682-695.
PubMed
22) Sarwar CM, et al.:Hyperkalemia in Heart Failure. J Am Coll Cardiol 2016;68:1575-1589.
PubMed
Crees Z, et al., eds., 高久史麿, 他 監訳:ワシントンマニュアル第14版. メディカル・サイエンス・インターナショナル, 2021(Crees Z, et al., eds.:The Washington Manual of Medical Therapeutics, 36th ed. Wolters Kluwer, 2019).
 
日本高血圧学会高血圧治療ガイドライン作成委員会 編:高血圧治療ガイドライン2019. ライフサイエンス出版, 2019. https://www.jpnsh.jp/data/jsh2019/JSH2019_hp.pdf(2022年6月閲覧)
 
日本高血圧学会高血圧診療ガイド2020作成委員会 編:高血圧診療ガイド. 文光堂, 2020.
 

書評

最近チェックした商品履歴

Loading...